Management of Valvular Heart Disease

161 question(s) with answers and explanations.

Question 1

A 28-year-old female who recently immigrated from a low-income country presents to the cardiology clinic with progressive dyspnea on exertion, orthopnea, and occasional hemoptysis. Physical examination reveals a loud S1, an opening snap, and a low-pitched mid-diastolic rumble at the cardiac apex. Multimodality imaging is utilized to determine the pathophysiology and assess the severity of her valvular heart disease (VHD). Based on her region of origin, what is the principal cause of this patient's underlying valvular pathology?

• ✓ Rheumatic heart disease
• ○ Degenerative calcific disease
• ○ Congenital valve malformation
• ○ Infective endocarditis

Explanation. The patient's clinical presentation indicates mitral stenosis, and rheumatic heart disease remains the principal cause of valvular heart disease in middle- and lower-income countries.

Question 2

A 65-year-old male with a history of rheumatic fever presents with progressive dyspnea on exertion and orthopnea. Physical examination reveals a loud S1, an opening snap, and a low-pitched mid-diastolic murmur at the cardiac apex. Initial comprehensive transthoracic echocardiography (TTE) confirms the presence of mitral stenosis (MS) but provides suboptimal visualization of the mitral valve (MV) apparatus and left atrial appendage due to poor acoustic windows. Which of the following imaging modalities has a central diagnostic role and is most appropriate to further evaluate the MV anatomy and rule out thrombosis in this patient?

• ✓ Transoesophageal echocardiography (TOE)
• ○ Cardiac magnetic resonance (CMR) imaging
• ○ Cardiac computed tomography (CCT) for calcium scoring
• ○ Radionuclide ventriculography

Explanation. Transoesophageal echocardiography (TOE) has a central diagnostic role in specific clinical scenarios, including the evaluation of mitral stenosis, detailed assessment of mitral valve anatomy, and the detection of thrombosis, particularly when initial transthoracic echocardiography is of poor quality or inconclusive.

Question 3

A 68-year-old man is evaluated for progressive dyspnea and fatigue. Physical examination reveals a bounding pulse and a blowing, decrescendo diastolic murmur at the left sternal border. Transthoracic echocardiography (TTE) confirms aortic regurgitation (AR), but the quantitative severity is equivocal due to suboptimal acoustic windows. Which advanced imaging modality has gained key value in clinical practice specifically for the detailed evaluation and quantification of this regurgitant lesion?

• ✓ Cardiac magnetic resonance (CMR)
• ○ Single-photon emission computed tomography (SPECT)
• ○ Positron emission tomography (PET)
• ○ Nuclear scintigraphy

Explanation. Cardiac magnetic resonance (CMR) has gained key value in clinical practice for the detailed evaluation and quantification of regurgitant lesions, particularly aortic regurgitation.

Question 4

A 68-year-old male with known severe aortic stenosis (AS) presents for clinical evaluation. He reports no functional limitations and states he is completely asymptomatic during his daily activities. A resting transthoracic echocardiography (TTE) reveals a peak aortic jet velocity of 4.3 m/s, a mean transvalvular gradient of 44 mmHg, and a normal left ventricular ejection fraction of 62%. To best unveil potential hidden symptoms, assess dynamic changes in valvular severity, and refine the indication for intervention, which of the following is the most appropriate next diagnostic step?

• ✓ Exercise echocardiography
• ○ Pharmacological dobutamine stress echocardiography
• ○ Cardiac magnetic resonance (CMR) imaging
• ○ Transesophageal echocardiography (TEE)

Explanation. Exercise echocardiography is highly valuable in the assessment of valvular heart disease to unveil symptoms in apparently asymptomatic patients, identify dynamic changes in valvular severity, and refine the indication for an intervention, particularly in conditions such as aortic stenosis and mitral regurgitation.

Question 5

A 78-year-old male with severe, symptomatic mitral regurgitation and multiple comorbidities is evaluated for a transcatheter mitral valve replacement. To adequately plan the procedure, the structural heart team needs to accurately size the prosthesis, delineate the extent of mitral annular calcification (MAC), and evaluate the precise spatial relationship of the mitral valve apparatus with the left ventricular outflow tract (LVOT) to predict the risk of LVOT obstruction. Which of the following imaging modalities is most appropriate for obtaining these specific pre-procedural measurements?

• ○ Transoesophageal echocardiography (TOE) with 3D views
• ✓ Cardiac computed tomography (CCT)
• ○ Cardiac magnetic resonance (CMR) imaging
• ○ Coronary CT angiography (CCTA)

Explanation. Cardiac computed tomography (CCT) is utilized to evaluate the relationship of the valve with adjacent structures such as the coronary arteries and the left ventricular outflow tract, to assess the extension of calcification like mitral annular calcification, and to provide accurate sizing of the prosthesis.

Question 6

A 78-year-old woman with severe symptomatic aortic stenosis and multiple comorbidities is being evaluated by the Heart Team for surgical aortic valve replacement. During the multidisciplinary meeting, the team discusses estimating her surgical risk using established scoring systems. Which of the following statements regarding the use of these risk scores is most accurate?

• ○ The logistic EuroSCORE I model is preferred because it avoids the systematic overestimation of surgical mortality seen in newer models.
• ○ The Society of Thoracic Surgeons predicted risk of mortality (STS-PROM) score is a static model that cannot account for changes in patient risk profiles over time.
• ○ Risk stratification tools for valvular heart disease have been primarily developed based on transcatheter, rather than surgical, patient populations.
• ✓ Both EuroSCORE II and STS-PROM are commonly used scoring systems that have been calibrated to predict post-operative outcomes.

Explanation. The EuroSCORE II and the Society of Thoracic Surgeons predicted risk of mortality (STS-PROM) score are the most widely utilized scoring systems to estimate surgical risk in patients with valvular heart disease, and both risk scores have been specifically calibrated to predict post-operative outcomes.

Question 7

A 72-year-old man with a history of recurrent right-sided heart failure is evaluated for severe peripheral edema, hepatic congestion, and ascites. Transthoracic echocardiography reveals massive isolated tricuspid regurgitation with a structurally normal left ventricle. The multidisciplinary team is considering him for a first-time isolated tricuspid valve (TV) surgery. To properly counsel the patient and evaluate procedural mortality risk, the team discusses the optimal risk stratification tool. Which of the following is the most appropriate risk scoring strategy for this patient?

• ✓ Utilize the TRI-SCORE, which is specifically calibrated for isolated TV surgery.
• ○ Apply standard surgical risk scores since they do not overestimate risk in isolated valve interventions.
• ○ Implement models designed for mitral transcatheter edge-to-edge repair (M-TEER) due to their high external validity.
• ○ Utilize survival scores designed for transcatheter aortic valve implantation (TAVI) as they offer superior predictive performance.

Explanation. The TRI-SCORE is a dedicated clinical scoring tool that has been specifically calibrated and validated to stratify the risk associated with first-time and repeat isolated tricuspid valve surgery. Its application is encouraged for patients with tricuspid valve disease to accurately assess procedural risk as an alternative to the more complex Society of Thoracic Surgeons (STS) score.

Question 8

A 74-year-old female presents with symptomatic severe aortic stenosis, complaining of worsening exertional dyspnea over the past six months. Her past medical history is significant for Hodgkin lymphoma treated with mediastinal radiation therapy 40 years ago. A chest computed tomography (CT) scan reveals a porcelain aorta. The Heart Team is evaluating her for either surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI). Which of the following best describes how her specific clinical characteristics should influence the choice of intervention?

• ✓ Her history of mediastinal radiation therapy and the presence of a porcelain aorta significantly increase her surgical risk, thereby favoring a transcatheter treatment option.
• ○ The presence of a porcelain aorta requires concomitant open surgical resection and graft replacement, definitively favoring surgical aortic valve replacement.
• ○ Her previous mediastinal radiation therapy causes severe vascular and tissue fibrosis, which is an absolute contraindication to transcatheter aortic valve implantation.
• ○ Standard surgical risk models appropriately capture the risk conferred by a porcelain aorta and previous radiation therapy, making both approaches equally viable based on the calculated score.

Explanation. Specific unfavorable characteristics such as a porcelain aorta, mobile aortic atheroma, and previous mediastinal radiation therapy increase surgical risk, which favors the use of transcatheter treatment options over open surgery.

Question 9

A 72-year-old asymptomatic male with severe aortic stenosis presents for a routine follow-up. Echocardiography shows stable parameters since his last visit 6 months ago. To further stratify his risk and help determine the most appropriate timing for intervention, his cardiologist orders biomarker testing. Which of the following biomarker parameters has been shown to be a powerful, independent, and incremental predictor of mortality in this patient population?

• ○ The absolute value of N-terminal pro-B-type natriuretic protein (NT-proBNP) without adjustment
• ○ The absolute peak level of high-sensitivity cardiac troponin T
• ✓ The natriuretic peptide ratio (measured BNP or NT-proBNP to the upper limit of normal for age, sex, and assay)
• ○ The ratio of measured high-sensitivity cardiac troponin to brain natriuretic peptide (BNP)

Explanation. In patients with valvular heart disease, the natriuretic peptide ratio—defined as the ratio of measured brain natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic protein (NT-proBNP) to the upper limit of normal for age, sex, and assay—is a powerful, independent, and incremental predictor of mortality.

Question 10

A 74-year-old man with severe aortic stenosis (AS) presents for a routine evaluation. He reports feeling entirely well and denies experiencing any dyspnea, angina, or presyncope. However, his family notes that over the past two years, he has gradually stopped his daily two-mile walks and mostly remains sedentary, which the patient attributes to "normal aging." A treadmill exercise test is ordered. What is the most critical rationale for performing exercise testing in this specific clinical scenario?

• ✓ To objectively unmask symptoms, as the onset of symptoms represents a sharp increase in the risk of sudden cardiac death.
• ○ To quantify the baseline left ventricular global longitudinal strain for accurate prognostic risk stratification.
• ○ To document exercise-induced secondary mitral regurgitation in order to guide combined valvular intervention.
• ○ To induce a transient reduction in pulmonary artery pressure to confirm the precise hemodynamic severity of the stenosis.

Explanation. Patients with progressive valvular lesions often subconsciously limit their physical activity over time to avoid discomfort, leading to a false clinical presentation of being completely asymptomatic. Exercise testing is utilized to objectively evaluate functional capacity and unmask these hidden symptoms. In cases of severe aortic stenosis, unmasking symptoms is of paramount importance because symptom onset serves as a critical clinical threshold that heralds a sharp escalation in the risk of sudden cardiac death unless a valve intervention is promptly performed.

Question 11

A 64-year-old woman presents with progressive exertional dyspnea. Transthoracic echocardiography shows rheumatic mitral valve changes, but the hemodynamic severity of the mitral valve disease is equivocal. She has no history of angina and is determined to be at low risk for obstructive coronary artery disease (CAD). A percutaneous mitral valve intervention is being considered by the Heart Team. Which of the following strategies is most appropriate for her pre-procedural diagnostic assessment?

• ✓ Right heart catheterization (RHC) performed in a euvolemic state and coronary computed tomography angiography (CCTA)
• ○ Right heart catheterization (RHC) performed in a hypervolemic state and invasive coronary angiography
• ○ Left heart catheterization with transaortic gradients and fractional flow reserve (FFR)
• ○ Invasive coronary angiography with functional hemodynamic assessment using fractional flow reserve (FFR)

Explanation. Right heart catheterization (RHC) is indicated to clarify hemodynamics when echocardiographic findings of mitral valve disease are equivocal, and it should ideally be performed while the patient is in a euvolemic state to accurately assess volume status, cardiac output, and vascular resistance. Furthermore, coronary computed tomography angiography (CCTA) is the appropriate alternative to invasive coronary angiography to rule out concomitant coronary artery disease (CAD) prior to a planned intervention in patients who are at low or moderate risk for obstructive CAD.

Question 12

A 68-year-old woman presents with worsening peripheral edema and fatigue. Transthoracic echocardiography reveals severe tricuspid regurgitation (TR), a dilated right atrium, and reduced right ventricular (RV) systolic function. The estimated systolic pulmonary artery pressure is 35 mmHg. She undergoes right heart catheterization for further hemodynamic evaluation. During the procedure, significant 'ventricularization' of the right atrial pressure curve is noted. Which of the following is the most appropriate next step to accurately assess for concomitant pulmonary vascular disease?

• ✓ Calculate the pulmonary vascular resistance (PVR)
• ○ Measure the amplitude of the pulmonary capillary wedge pressure v-wave
• ○ Perform an exercise right heart catheterization
• ○ Administer inhaled nitric oxide to assess for vasoreactivity

Explanation. In patients with severe tricuspid regurgitation, pulmonary vascular disease may be masked on echocardiography due to right ventricular systolic dysfunction or the underestimation of pulmonary pressures caused by the severe regurgitation. Therefore, calculating pulmonary vascular resistance is necessary to accurately unmask underlying pulmonary vascular disease.

Question 13

A 55-year-old male with severe rheumatic mitral valve stenosis and regurgitation presents to the cardiology clinic to discuss treatment options. He is an active musician who plays the violin in a symphony orchestra and travels frequently for performances. A multidisciplinary Heart Valve Team recommends surgical mitral valve replacement. The patient is anxious about the procedure and uncertain whether to choose a mechanical or bioprosthetic valve. As part of a comprehensive, patient-centered shared decision-making process, which of the following combinations of topics must be discussed with the patient prior to the intervention?

• ○ The necessity for dual antiplatelet therapy for life, center volume for the procedure, and a guarantee of returning to his prior level of musical performance within two weeks.
• ✓ The symptomatic and prognostic benefits of the surgery, the noise generated by mechanical heart valves, the requirement for oral anticoagulation, and the provision of a clearly defined point of contact for all questions.
• ○ The assurance that mechanical heart valves require no further reinterventions, the omission of mortality risks to avoid exacerbating his anxiety, and the mandatory requirement for a permanent pacemaker.
• ○ The delegation of all treatment decisions entirely to the patient without providing center-specific outcome data, to ensure a completely unbiased and independent choice.

Explanation. Essential components of comprehensive patient education prior to valvular interventions include discussing the symptomatic and prognostic benefits, mortality and risks of complications, the need for oral anticoagulation and its monitoring, the noise generated by mechanical heart valves, and establishing a clearly defined point of contact for the patient and their relatives.

Question 14

A 78-year-old female with severe symptomatic aortic stenosis is being evaluated for transcatheter aortic valve implantation (TAVI). She has no history of typical angina or prior myocardial infarction. Her estimated pre-test likelihood of obstructive coronary artery disease (CAD) is calculated to be 35%. The Heart Team is preparing to discuss her case and determine the optimal treatment modality, but requires assessment of her coronary anatomy prior to the meeting. Which of the following is the most appropriate initial diagnostic study to evaluate for relevant CAD in this patient?

• ✓ Coronary computed tomography angiography (CCTA)
• ○ Invasive coronary angiography (ICA)
• ○ Dobutamine stress echocardiography
• ○ Single-photon emission computed tomography (SPECT) myocardial perfusion imaging

Explanation. In patients with a low or moderate pre-test likelihood of obstructive coronary artery disease (≤50%), coronary computed tomography angiography (CCTA) is recommended to rule out relevant CAD with high sensitivity prior to Heart Team discussion and decision-making.

Question 15

An 82-year-old man with severe symptomatic aortic stenosis (AS) is being evaluated for transcatheter aortic valve implantation (TAVI). Pre-procedure coronary computed tomography (CCT) angiography reveals an intermediate stenosis in the mid-left anterior descending artery. The cardiology team discusses performing invasive coronary angiography with functional hemodynamic assessment to evaluate the physiological significance of the coronary lesion prior to the valve intervention. Which of the following is the most important consideration regarding functional hemodynamic assessment in this patient?

• ✓ Severe aortic stenosis alters coronary hemodynamics, which may limit the value and interpretability of invasive functional measurements.
• ○ Invasive functional assessment is the definitive standard in severe aortic stenosis and should routinely dictate pre-TAVI revascularization.
• ○ Functional hemodynamic assessment requires prior exclusion of coronary artery calcification and atrial fibrillation to be clinically valid.
• ○ The procedure is strictly contraindicated due to the high risk of hemodynamic collapse during hyperemic agent administration in severe aortic stenosis.

Explanation. The value of invasive functional hemodynamic assessment of coronary artery disease is limited in the setting of severe aortic stenosis because the valvular disease itself significantly impacts coronary hemodynamics, warranting caution in the interpretation of functional measurements.

Question 16

A 74-year-old man presents with progressive exertional dyspnea and angina. Transthoracic echocardiogram reveals severe aortic stenosis (AS) with a calculated valve area of 0.7 cm^2 and a mean gradient of 52 mmHg. Left ventricular (LV) ejection fraction is 55%. He is scheduled for surgical aortic valve replacement (SAVR). Pre-operative coronary angiography reveals an 80% stenosis in the mid-left anterior descending coronary artery. What is the most appropriate surgical management regarding his coronary artery disease?

• ✓ Concomitant coronary artery bypass grafting (CABG) during the SAVR procedure.
• ○ Isolated SAVR, as the improvement in cardiac output and reduction in LV wall stress will adequately resolve his angina.
• ○ Isolated SAVR, because the increased peri-procedural risk of prolonged cross-clamp time outweighs the long-term benefits of combined surgery.
• ○ Deferral of any coronary revascularization unless the patient demonstrates persistent angina post-operatively.

Explanation. In patients with a primary indication for surgical valve replacement who have coexisting coronary artery disease, concomitant coronary artery bypass grafting (CABG) is recommended when there is a coronary artery stenosis of 70% or greater. Performing combined surgical aortic valve replacement (SAVR) and CABG in these patients results in better long-term survival compared with isolated SAVR by mitigating the peri-operative and late adverse events associated with untreated coronary artery disease, which provides a benefit that outweighs the risks of a longer cross-clamp time.

Question 17

A 79-year-old man with severe symptomatic aortic stenosis (AS) is scheduled to undergo transcatheter aortic valve implantation (TAVI). Pre-procedural coronary angiography reveals a 95% stenosis in the mid-left circumflex artery with a reference vessel diameter of 2.8 mm. He has no angina, but is functionally limited by dyspnea on exertion. The Heart Team debates whether to perform percutaneous coronary intervention (PCI) of this lesion or to pursue conservative management of the coronary disease. What is the expected outcome of pursuing a routine PCI strategy compared to conservative management for this patient?

• ✓ Lower risk of a composite of all-cause death, myocardial infarction, or urgent revascularization, accompanied by a higher risk of bleeding.
• ○ Lower risk of stroke and myocardial infarction, accompanied by a lower risk of bleeding.
• ○ No difference in the risk of myocardial infarction or urgent revascularization, but a higher risk of periprocedural mortality.
• ○ Higher risk of all-cause mortality due to an increased incidence of major bleeding events.

Explanation. Performing routine percutaneous coronary intervention (PCI) in patients with severe symptomatic aortic stenosis and severe stable coronary artery disease (e.g., diameter stenosis >=90%) undergoing transcatheter aortic valve implantation (TAVI) is associated with a lower risk of a composite endpoint event including all-cause death, myocardial infarction, or urgent revascularization at follow-up, but carries a higher risk of bleeding compared to conservative management.

Question 18

An 82-year-old male with severe, symptomatic aortic stenosis is evaluated for a transcatheter aortic valve implantation (TAVI). Pre-procedural coronary angiography reveals a 75% stenosis in the mid-right coronary artery and a 70% stenosis in the mid-left circumflex artery. The patient has no active angina, and his history is consistent with chronic coronary artery disease (CAD). The interventional cardiologist considers performing prophylactic percutaneous coronary intervention (PCI) on these lesions prior to TAVI. What is the anticipated outcome of pursuing a routine PCI strategy for this patient's CAD compared to conservative management?

• ○ It will significantly decrease the long-term risk of all-cause mortality following the valve intervention.
• ✓ It will not provide a mortality benefit and is associated with a higher rate of bleeding complications.
• ○ It will significantly reduce the short-term incidence of acute coronary syndrome post-TAVI.
• ○ It will improve the composite outcome of all-cause death and rehospitalization by establishing non-inferiority.

Explanation. In patients with chronic coronary artery disease undergoing transcatheter aortic valve implantation (TAVI), a routine percutaneous coronary intervention (PCI) strategy for ≥70% stenoses in main epicardial vessels does not provide a mortality benefit and is associated with higher bleeding rates. Furthermore, TAVI can be performed safely in patients with untreated coronary artery disease with low short- and long-term rates of acute coronary syndrome and unplanned coronary revascularization.

Question 19

An 81-year-old male is scheduled to undergo transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis. Pre-procedural coronary angiography reveals a complex, heavily calcified lesion in the proximal left anterior descending artery. Pre-procedural imaging also demonstrates a narrow aortic root. The Heart Team is discussing the optimal transcatheter valve selection and the timing of percutaneous coronary intervention (PCI). Which of the following factors is most critical to consider because it can pose significant challenges for future coronary access following the TAVI procedure?

• ○ The decision to perform PCI concomitantly with TAVI rather than as a staged procedure beforehand.
• ○ The routine use of a low-frame transcatheter valve without commissural alignment.
• ○ The presence of significant coronary artery disease irrespective of the chosen valve's frame height.
• ✓ The use of a transcatheter valve with a high frame in the setting of a narrow aortic root.

Explanation. Valves with a high frame, particularly in the context of a narrow aortic root, commissural misalignment, or valve-in-valve procedures, can pose significant challenges for coronary access following transcatheter aortic valve implantation (TAVI). The presence of significant coronary artery disease and anatomical factors like a narrow aortic root must therefore be considered to guide optimal transcatheter valve selection and reinforce the importance of optimized implantation technique to preserve future coronary access.

Question 20

An 81-year-old male with severe, symptomatic aortic stenosis is evaluated by the Heart Team and accepted for transcatheter aortic valve implantation (TAVI) due to prohibitive surgical risk. He reports progressive dyspnea on exertion but denies any typical angina. Pre-procedural coronary angiography reveals a 95% stenosis in the mid-left anterior descending (LAD) artery, with a reference vessel diameter of 2.8 mm. Which of the following is the most appropriate management strategy for this patient's coronary artery disease?

• ✓ Perform percutaneous coronary intervention (PCI) of the mid-left anterior descending artery.
• ○ Proceed with TAVI and defer percutaneous coronary intervention (PCI) since the patient does not report typical angina.
• ○ Perform surgical aortic valve replacement combined with coronary artery bypass grafting instead of TAVI.
• ○ Manage the coronary stenosis medically, as percutaneous coronary intervention (PCI) is reserved only for lesions causing elevated troponin levels in this setting.

Explanation. Percutaneous coronary intervention (PCI) should be considered in patients who have a primary indication to undergo transcatheter aortic valve implantation (TAVI) and concurrently present with high-grade (≥90%) coronary artery stenosis in large vessels with a diameter greater than 2.5 mm. This patient's 95% stenosis in a 2.8 mm vessel meets these anatomical criteria, making PCI the appropriate clinical intervention.

Question 21

A 79-year-old man with severe symptomatic aortic stenosis (AS) and permanent atrial fibrillation (AF) is evaluated for transcatheter aortic valve implantation (TAVI). The structural heart team debates whether to perform concomitant transcatheter left atrial appendage occlusion (LAAO) during the procedure instead of continuing standard medical therapy for his AF. Based on recent randomized controlled trial data evaluating this combined approach, what is the most likely outcome regarding adverse events when comparing concomitant TAVI and LAAO to TAVI with medical therapy?

• ○ A significant reduction in major or life-threatening bleeding.
• ✓ Similar rates of major bleeding and higher rates of arterial or venous thromboembolism.
• ○ Lower rates of arterial or venous thromboembolism with similar rates of major bleeding.
• ○ Superiority in the composite endpoint of all-cause mortality, stroke, and major bleeding.

Explanation. In patients with severe aortic stenosis and atrial fibrillation undergoing transcatheter aortic valve implantation, concomitant transcatheter left atrial appendage occlusion is non-inferior to medical therapy for a composite endpoint of all-cause mortality, stroke, and major bleeding. However, major or life-threatening bleeding rates are similar between the groups, and arterial or venous thromboembolisms are more frequent with the combined approach, leaving uncertainty regarding the usefulness of combining both procedures.

Question 22

A 68-year-old woman with a history of permanent atrial fibrillation (AF) for the past 4 years presents for a routine echocardiogram. Her baseline echocardiogram from 4 years ago showed normal valvular function and no structural heart disease. Based on the natural history of her condition, which of the following valvular abnormalities is she at increased risk of developing directly as a result of her chronic AF?

• ✓ Atrial secondary mitral and tricuspid regurgitation
• ○ Calcific aortic stenosis
• ○ Primary mitral valve prolapse
• ○ Secondary aortic regurgitation

Explanation. Atrial fibrillation is a major trigger for the development of atrial secondary mitral and tricuspid regurgitation, which is postulated to occur as a result of disturbed annular dynamics.

Question 23

A 62-year-old female presents with new-onset palpitations and shortness of breath. An electrocardiogram (ECG) confirms atrial fibrillation (AF). Transthoracic echocardiography reveals a thickened mitral valve with restricted leaflet motion and a calculated mitral valve area of 1.4 cm². She has no prior history of surgical valve replacement. Which of the following is the most appropriate long-term oral anticoagulation strategy for the prevention of thromboembolic complications in this patient?

• ✓ A vitamin K antagonist (VKA)
• ○ Apixaban
• ○ Dabigatran
• ○ Rivaroxaban

Explanation. Patients presenting with atrial fibrillation (AF) in the setting of mitral stenosis with a valve area of less than 2.0 cm² require anticoagulation with a vitamin K antagonist (VKA), as direct oral anticoagulants (DOACs) are specifically excluded from use in this patient population.

Question 24

A 76-year-old male with a history of hypertension, type 2 diabetes mellitus, and persistent atrial fibrillation (AF) is scheduled to undergo coronary artery bypass grafting. His CHA2DS2-VASc score is 4. His medical team plans to continue his direct oral anticoagulant (DOAC) postoperatively. During the preoperative case conference, the surgeon suggests performing concomitant surgical left atrial appendage occlusion (LAAO). What is the expected impact of performing surgical LAAO in this patient?

• ✓ It significantly reduces the risk of stroke or systemic embolism, and this benefit remains consistent despite the planned use of a DOAC.
• ○ It provides no additional stroke risk reduction because the patient will be continuously treated with a DOAC.
• ○ It is associated with a reduction in stroke risk only if the patient is transitioned to a vitamin K antagonist (VKA) postoperatively.
• ○ It reduces the risk of stroke or systemic embolism but is only indicated if the patient is completely unable to tolerate oral anticoagulation.

Explanation. In patients with atrial fibrillation and a CHA2DS2-VASc score of 2 or greater undergoing cardiac surgery, concomitant surgical left atrial appendage occlusion (LAAO) reduces the risk of stroke or systemic embolism by approximately 33%. This clinical benefit remains consistent irrespective of the use of direct oral anticoagulants (DOACs), vitamin K antagonists, or the absence of oral anticoagulation, providing additional protection beyond pharmacologic therapy alone.

Question 25

A 32-year-old woman presents to the clinic for a routine cardiovascular health evaluation. She has a history of Hodgkin lymphoma for which she received mantle field radiotherapy exactly 10 years ago at age 22. She is currently asymptomatic, exercises regularly without difficulty, and her cardiovascular examination is unremarkable with no audible murmurs. What is the most appropriate screening and follow-up strategy for valvular heart disease (VHD) in this patient?

• ✓ Perform a transthoracic echocardiogram (TTE) now, and follow up every 5 years thereafter.
• ○ Perform a transthoracic echocardiogram (TTE) now, and follow up every 10 years thereafter.
• ○ Defer echocardiographic screening until the patient develops symptoms or a new murmur is auscultated.
• ○ Perform a transthoracic echocardiogram (TTE) 20 years after the initial radiation exposure, and every 5 years thereafter.

Explanation. Patients at risk for radiation-induced valvular heart disease, such as those who have received radiotherapy for thoracic malignancies like Hodgkin lymphoma, should undergo screening with a transthoracic echocardiogram 10 years after radiation exposure and be followed up every 5 years thereafter. Because this patient is exactly 10 years post-exposure, an initial screening TTE is indicated at this visit, with subsequent evaluations spaced at 5-year intervals.

Question 26

A 65-year-old female presents with progressive dyspnea on exertion. Her medical history is notable for Hodgkin lymphoma treated with mantle field chest radiotherapy 25 years ago. Echocardiography demonstrates severe aortic stenosis and severe mitral regurgitation. The mitral valve leaflets are notably thickened with restricted mobility. The Heart Team is evaluating her for transcatheter interventions, including transcatheter aortic valve implantation (TAVI) and mitral transcatheter edge-to-edge repair (M-TEER). Which of the following is an important consideration regarding M-TEER for this patient?

• ✓ M-TEER is often limited by her thickened leaflets and restricted movement, leading to an increased risk of iatrogenic mitral stenosis.
• ○ M-TEER provides superior outcomes to surgical mitral valve replacement because traditional surgical risk scores accurately reflect a low operative risk.
• ○ M-TEER is preferred as a combined procedure with TAVI because radiotherapy facilitates tissue healing and reduces the risk of pericardial adhesions.
• ○ M-TEER has a significantly lower complication rate in radiation-induced valvular disease compared to age-matched controls without a history of cancer.

Explanation. In patients presenting with radiation-induced mitral valve disease accompanied by mitral regurgitation, the leaflets are frequently thickened and exhibit restricted movement. These structural and functional changes limit the efficacy of mitral transcatheter edge-to-edge repair (M-TEER) and predispose the patient to a subsequent risk of developing iatrogenic mitral stenosis following the procedure.

Question 27

A 15-year-old female recently immigrated from a rural region and is evaluated at the cardiology clinic for a newly discovered heart murmur. She is asymptomatic and active. Transthoracic echocardiogram reveals thickened mitral valve leaflets with commissural fusion, consistent with established rheumatic heart disease. To prevent recurrent episodes of acute rheumatic fever, what is the most appropriate secondary prophylactic regimen for this patient?

• ✓ Intramuscular benzathine benzyl penicillin 1.2 million international units (IU) every 3-4 weeks over 10 years
• ○ Oral amoxicillin 500 mg daily over 5 years
• ○ Intramuscular benzathine benzyl penicillin 1.2 million international units (IU) every 6 months into adulthood
• ○ Oral penicillin V 250 mg twice daily indefinitely

Explanation. In patients with established rheumatic heart disease, secondary long-term prophylaxis with benzathine benzyl penicillin 1.2 million international units (IU) administered every 3-4 weeks over a period of 10 years is the recommended strategy to prevent recurrent episodes of acute rheumatic fever, particularly in children and adolescents.

Question 28

A 55-year-old male presents to the intensive care unit in cardiogenic shock secondary to acute severe aortic regurgitation (AR). He is endotracheally intubated and requires escalating doses of vasopressors. Emergency surgical valve replacement is planned, but the patient remains profoundly hypotensive with poor end-organ perfusion. Which of the following is a recognized temporizing measure to improve hemodynamics in this specific clinical scenario while awaiting surgery?

• ✓ Fast pacing via a temporary pacemaker lead
• ○ Balloon aortic valvuloplasty
• ○ Intravenous administration of a beta-blocker to prolong diastole
• ○ Transcatheter aortic valve implantation (TAVI)

Explanation. Fast pacing over a temporary pacemaker lead shortens diastole, which limits the time available for regurgitant blood to flow back into the left ventricle, thereby temporarily improving hemodynamics until definitive surgical intervention is performed.

Question 29

A 68-year-old male is admitted with an acute inferior myocardial infarction. Despite successful primary percutaneous coronary intervention, he develops cardiogenic shock requiring mechanical circulatory support. Echocardiography reveals severe acute ventricular secondary mitral regurgitation (SMR) without papillary muscle rupture or intrinsic leaflet abnormalities. To improve survival and facilitate weaning from mechanical circulatory support, which of the following is the most appropriate management strategy for his mitral regurgitation?

• ✓ Mitral transcatheter edge-to-edge repair (M-TEER)
• ○ Surgical mitral valve replacement
• ○ Surgical mitral valve repair with an undersized annuloplasty ring
• ○ Maximal medical therapy and mechanical support without structural intervention

Explanation. In patients with acute ventricular secondary mitral regurgitation, particularly following an acute myocardial infarction, mitral transcatheter edge-to-edge repair (M-TEER) is associated with lower mortality compared to surgical or medical treatment. It is an effective strategy to address the valvular pathology and facilitate weaning from mechanical circulatory support.

Question 30

A 55-year-old man with a known history of a bicuspid aortic valve (BAV) presents for a routine follow-up evaluation. He is completely asymptomatic and reports no limitations in his functional capacity. Vital signs show a heart rate of 72 bpm and an acutely elevated systemic blood pressure of 180/105 mmHg. A transthoracic echocardiogram is performed, demonstrating aortic regurgitation (AR) with a calculated regurgitant volume (RVol) of 65 mL/beat, a value typically indicative of severe AR. His left ventricular ejection fraction is 60%. Which of the following is the most accurate statement regarding the assessment of his valvular disease severity?

• ✓ The patient's elevated systemic blood pressure can lead to an overestimation of the regurgitant volume.
• ○ The patient's elevated systemic blood pressure likely causes an underestimation of the regurgitant volume.
• ○ The presence of a bicuspid aortic valve requires severity evaluation solely by cardiac magnetic resonance (CMR) rather than echocardiography.
• ○ The acute elevation in blood pressure is highly specific for an acute extension of an aortic dissection into the aortic root.

Explanation. During the evaluation of aortic regurgitation severity, the hemodynamic condition of the patient, particularly the systemic blood pressure, must be taken into consideration because high blood pressures can lead to an overestimation of the regurgitant volume.

Question 31

A 42-year-old asymptomatic male with severe chronic aortic regurgitation (AR)—evidenced by a large central jet occupying 70% of the left ventricular outflow tract (LVOT) diameter—is being evaluated in the clinic. Standard two-dimensional (2D) transthoracic echocardiography (TTE) demonstrates borderline left ventricular (LV) enlargement and an LV ejection fraction of 52%. The clinical team is attempting to determine the optimal timing for intervention. Which of the following approaches is most appropriate to further assess this patient's LV volumes and underlying function?

• ✓ Perform three-dimensional (3D) echocardiography or cardiovascular magnetic resonance (CMR) for volume evaluation, and utilize strain imaging to identify subclinical LV dysfunction.
• ○ Rely exclusively on standard 2D echocardiography since all established cut-offs for surgical intervention are based solely on 2D measurements.
• ○ Proceed directly to stress echocardiography to assess diastolic reserve as the primary determinant for valve replacement.
• ○ Measure the descending thoracic aorta to determine the specific aortic phenotype and establish suitability for valve repair.

Explanation. Three-dimensional (3D) echocardiography and cardiovascular magnetic resonance (CMR) provide a more accurate evaluation of left ventricular volumes and ejection fraction than standard 2D echocardiography, making them highly useful in borderline clinical cases. Furthermore, strain imaging helps identify subclinical left ventricular dysfunction, yielding critical information that influences the optimal timing of surgical intervention.

Question 32

A 35-year-old male presents for a routine evaluation and is found to have a diastolic murmur. Echocardiography reveals severe aortic regurgitation (AR) secondary to a bicuspid aortic valve (BAV), along with a dilated ascending aorta measuring 48 mm. The patient is highly active and wishes to avoid a prosthetic valve replacement if possible. The heart team is considering an aortic valve (AV) repair or an AV-sparing procedure. Which of the following echocardiographic features of the BAV is an important predictor of reparability and better long-term results?

• ✓ A high degree of symmetry of the valve phenotype
• ○ An asymmetric valve phenotype with a prominent raphe
• ○ A normal aortic root diameter
• ○ The presence of holodiastolic flow reversal in the descending aorta

Explanation. The morphology of the aortic valve represents a critical aspect in the treatment of aortic regurgitation. When considering aortic valve repair or valve-sparing procedures for a bicuspid aortic valve, the degree of symmetry is an important predictor of reparability, with more symmetric phenotypes yielding better long-term results.

Question 33

A 68-year-old male with a history of chronic severe aortic regurgitation (AR) presents to the clinic. He has recently been diagnosed with symptomatic premature ventricular complexes, and the initiation of a beta-blocker is being considered to manage his palpitations. Which of the following describes the primary hemodynamic concern associated with initiating a beta-blocker in this patient?

• ✓ It prolongs the duration of diastole, which increases the regurgitant volume.
• ○ It significantly increases systemic vascular resistance, thereby increasing left ventricular afterload.
• ○ It reduces the systolic ejection time, causing a critical drop in forward stroke volume.
• ○ It decreases left ventricular compliance, directly worsening pulmonary venous congestion.

Explanation. The use of beta-blockers slows the heart rate and increases the length of diastole, which provides more time for blood to flow backward across the incompetent aortic valve, thereby directly increasing the regurgitant volume.

Question 34

A 68-year-old male presents with progressively worsening exertional angina. He undergoes coronary angiography, which reveals severe three-vessel coronary artery disease. Transthoracic echocardiography demonstrates preserved left ventricular (LV) systolic function with an ejection fraction of 60%, normal LV dimensions, and severe aortic regurgitation (AR). The patient denies dyspnea, orthopnea, or any symptoms of heart failure. He is scheduled to undergo coronary artery bypass grafting (CABG). Which of the following is the most appropriate management regarding his aortic valve?

• ○ Proceed with CABG alone and medically manage the severe aortic regurgitation.
• ✓ Perform concomitant aortic valve surgery along with CABG.
• ○ Perform transcatheter aortic valve implantation after a successful CABG.
• ○ Postpone CABG until the patient develops symptoms of left ventricular volume overload.

Explanation. Concomitant surgical treatment of severe aortic regurgitation (AR) is recommended, irrespective of symptoms, in patients who are already requiring coronary artery bypass grafting (CABG), ascending aorta surgery, or any other cardiac surgical procedures. Because this patient is already scheduled for CABG to treat his three-vessel coronary artery disease, addressing the severe AR surgically during the same operation is the appropriate management despite his lack of heart failure symptoms.

Question 35

A 45-year-old man presents for routine evaluation of known severe aortic regurgitation (AR). He leads a sedentary lifestyle but states he feels well and denies any dyspnea, angina, or fatigue with his regular daily activities. Transthoracic echocardiography confirms severe AR. The left ventricular ejection fraction (LVEF) is 58%, the left ventricular end-systolic diameter (LVESD) is 44 mm, and the left ventricular end-diastolic diameter (LVEDD) is 58 mm. His body surface area is 2.0 m². Based on these findings, what is the most appropriate next step in management?

• ○ Refer the patient for early surgical aortic valve replacement
• ✓ Perform exercise testing to objectively assess functional capacity
• ○ Initiate vasodilator therapy with an angiotensin-converting enzyme (ACE) inhibitor
• ○ Schedule a follow-up echocardiogram in 24 months without further evaluation today

Explanation. Exercise testing should be performed, when feasible, in patients with severe aortic regurgitation who do not report symptoms and do not meet the resting echocardiographic criteria for surgery (such as LVEF ≤ 50% or LVESD > 50 mm) in order to unmask potential subclinical functional impairment.

Question 36

A 42-year-old male is referred for surgical intervention due to severe symptomatic aortic regurgitation and an aortic root aneurysm measuring 54 mm. Intraoperative transesophageal echocardiography demonstrates pliable aortic valve cusps with normal motion. He has an active lifestyle and a long estimated life expectancy. The surgical team is highly experienced in complex aortic procedures. Based on the characteristics of this patient's aortic valve tissue and root enlargement, which procedure is associated with superior long-term mortality and overall morbidity (such as thromboembolism and endocarditis) compared to a composite valve graft (Bentall procedure)?

• ✓ Valve-sparing aortic root replacement
• ○ Aortic valve replacement with a mechanical prosthesis
• ○ Aortic valve replacement with a bioprosthesis
• ○ Transcatheter aortic valve implantation

Explanation. In patients with aortic root enlargement and good tissue quality (characterized by pliable aortic valve cusps with normal motion), a valve-sparing aortic root replacement has been demonstrated to be superior to the use of a composite valve graft (Bentall procedure) in terms of long-term mortality and overall morbidity (specifically regarding thromboembolism and endocarditis), and is therefore the favored approach in experienced centers for patients with a long life expectancy.

Question 37

An 80-year-old male with severe symptomatic aortic regurgitation (AR) is deemed ineligible for surgical aortic valve replacement due to severe frailty and multiple comorbidities. The Heart Team considers transcatheter aortic valve implantation (TAVI) at an experienced center. They opt to use a dedicated transcatheter valve device for AR rather than a non-dedicated device. When counseling the patient on the procedural risks specifically associated with dedicated TAVI devices for AR, which of the following complications should be highlighted as occurring at a notably high rate?

• ○ Need for a second valve implantation due to valve malpositioning
• ✓ High rate of new permanent pacemaker implantation
• ○ Unacceptable rates of severe residual aortic regurgitation
• ○ Surgical conversion due to device failure

Explanation. Dedicated transcatheter devices for aortic regurgitation appear to minimize the risk of valve migration and residual AR in selected patients, but they are associated with a notably high rate of new permanent pacemaker implantation (approximately 24%).

Question 38

A 42-year-old man with a bicuspid aortic valve and severe aortic stenosis presents with progressive dyspnea on exertion, establishing an indication for aortic valve surgery. Electrocardiographic-triggered cardiac computed tomography (CCT) confirms an ascending aorta diameter of 46 mm. What is the most appropriate surgical management regarding his ascending aorta?

• ✓ Perform concomitant surgery of the ascending aorta.
• ○ Perform aortic valve surgery alone, as concomitant ascending aorta replacement is indicated only for diameters ≥50 mm.
• ○ Perform aortic valve surgery alone, as concomitant ascending aorta replacement is indicated only for diameters >55 mm.
• ○ Postpone both aortic valve and ascending aorta surgeries until the aortic diameter reaches 50 mm.

Explanation. If a patient has an established indication for aortic valve surgery due to aortic regurgitation or aortic stenosis, concomitant surgery of the aortic root or the ascending aorta should be considered at a diameter of ≥45 mm. This threshold has been specifically demonstrated in patients with bicuspid aortic valves.

Question 39

A 32-year-old male with Marfan syndrome presents for routine cardiovascular follow-up. A baseline transthoracic echocardiography (TTE) performed 18 months ago demonstrated an aortic root diameter of 46 mm. A subsequent TTE at 6 months confirmed the stability of this finding. Today, the patient undergoes his scheduled yearly TTE, which reveals an aortic root diameter of 50 mm. He is asymptomatic. What is the most appropriate next step in the management of this patient?

• ✓ Validate the echocardiographic finding with computed tomography (CT) angiography or cardiovascular magnetic resonance (CMR) imaging.
• ○ Schedule the patient for immediate prophylactic ascending aortic repair.
• ○ Repeat the transthoracic echocardiography (TTE) in 6 months to monitor for further progression.
• ○ Initiate therapy with a continuous intravenous beta-blocker to reduce aortic wall stress.

Explanation. Any increase in aortic diameter of greater than 3 mm on serial echocardiographic assessment requires validation with computed tomography (CT) angiography or cardiovascular magnetic resonance (CMR) imaging, and comparison with baseline data.

Question 40

A 28-year-old asymptomatic man is found to have a bicuspid aortic valve (BAV) with moderate aortic regurgitation and an aortic root diameter of 42 mm during an evaluation for a newly detected murmur. He has no physical examination features suggestive of a connective tissue disease. He has two siblings and a 4-year-old daughter. He asks what steps, if any, should be taken regarding the cardiovascular health of his family members. What is the most appropriate recommendation?

• ✓ Encourage echocardiographic screening for his first-degree relatives.
• ○ Refer his first-degree relatives for comprehensive cardiovascular genetic testing.
• ○ Advise clinical examination for his family members, reserving echocardiography only for those with audible murmurs.
• ○ Perform routine screening of his first-degree relatives using cardiac magnetic resonance (CMR) imaging.

Explanation. Aortic dilation is present in approximately 10% of first-degree relatives of patients with a bicuspid aortic valve (BAV), making it appropriate to encourage proactive echocardiographic screening in this specific population.

Question 41

A 45-year-old male residing in North America presents to the cardiology clinic with progressive exertional dyspnea and a recent episode of syncope while climbing stairs. Transthoracic echocardiography reveals severe aortic stenosis (AS) with a heavily calcified aortic valve and a peak transvalvular velocity of 4.8 m/s. There is no evidence of concurrent mitral valve disease. He is referred for surgical aortic valve (AV) replacement. Based on the patient's demographics, what is the most likely dominant valve morphology causing his condition, and what associated anatomical finding must be carefully evaluated?

• ○ Degenerative trileaflet aortic valve; localized calcification of the mitral annulus
• ✓ Bicuspid aortic valve; dilatation of the aortic root or ascending aorta
• ○ Rheumatic aortic valve; concurrent severe right ventricular dilatation
• ○ Unicuspid aortic valve; localized left ventricular apical aneurysm

Explanation. In younger patients requiring aortic valve replacement for severe aortic stenosis, a bicuspid aortic valve constitutes the dominant underlying valve morphology. These valves are prone to earlier degeneration and calcification, and they are frequently associated with concurrent dilatation of the aortic root or ascending aorta.

Question 42

A 72-year-old woman presents with worsening exertional dyspnea and a harsh crescendo-decrescendo systolic ejection murmur at the right upper sternal border. A comprehensive transthoracic echocardiogram is ordered to evaluate suspected aortic stenosis (AS). The echocardiography report includes measurements for mean pressure gradient, peak transvalvular velocity, and effective aortic valve area (AVA). When interpreting these findings to grade the severity of her AS, which of the following principles is most accurate regarding these echocardiographic parameters?

• ✓ The mean pressure gradient is considered the most robust parameter for grading severity.
• ○ The effective AVA is the most robust parameter because it avoids the technical limitations associated with flow velocities.
• ○ Extravalvular cardiac damage is the most reliable metric for severity because it consistently follows a predictable chronological sequence.
• ○ Peak transvalvular velocity is theoretically the ideal parameter for assessing severity, despite its technical limitations in acquisition.

Explanation. The mean pressure gradient is the most robust echocardiographic parameter used for grading the severity of aortic stenosis, serving as a highly reliable measure compared to other metrics such as the effective aortic valve area, which, despite being theoretically ideal, carries numerous technical limitations in its calculation.

Question 43

A 74-year-old man presents with progressive exertional dyspnea and fatigue over the past 6 months. A transthoracic echocardiogram reveals a heavily calcified aortic valve with an aortic valve area (AVA) of 0.7 cm² and a mean transaortic gradient of 28 mmHg. His left ventricular ejection fraction (LVEF) is 38%, and his stroke volume index (SVi) is 30 mL/m². Which of the following is the most appropriate next step to distinguish between true severe and pseudo-severe valvular disease in this patient?

• ✓ Dobutamine stress echocardiography
• ○ Exercise treadmill stress echocardiography
• ○ Cardiac magnetic resonance imaging
• ○ Right heart catheterization

Explanation. In patients presenting with low-flow, low-gradient aortic stenosis with reduced left ventricular ejection fraction (characterized by a mean gradient <40 mmHg, aortic valve area ≤1 cm², stroke volume index ≤35 mL/m², and LVEF <50%), dobutamine stress echocardiography is utilized to discriminate between pseudo-severe and true severe aortic stenosis. This evaluation identifies the presence of flow reserve, defined as a stroke volume increase of ≥20%, which provides the necessary flow state to accurately determine the true severity of the stenotic valve.

Question 44

A 72-year-old man with a history of Hodgkin lymphoma treated with mantle field radiation therapy 35 years ago presents with progressive exertional dyspnea. Transthoracic echocardiography reveals an aortic valve area of 0.8 cm², a mean transvalvular gradient of 25 mmHg, and a left ventricular ejection fraction (LVEF) of 30%. To further assess the severity of his low-flow, low-gradient aortic stenosis (AS), a cardiac computed tomography (CCT) aortic valve calcium score is performed, yielding a result of 1450 Agatston units (AU). What is the most accurate interpretation of this calcium score?

• ○ Severe aortic stenosis is effectively ruled out because the score is below the strict threshold of 1600 AU for men.
• ✓ Severe aortic stenosis remains a strong possibility because radiation-induced valve disease can cause predominantly fibrotic stenosis without pronounced calcification.
• ○ Severe aortic stenosis is definitively confirmed because a score greater than 1200 AU is highly specific for severe disease in men.
• ○ The result is diagnostic of severe aortic stenosis because radiation therapy exponentially accelerates valvular calcium deposition.

Explanation. Severe aortic stenosis remains a clinical possibility in this patient because prior radiation therapy can cause severe valvular disease that is predominantly fibrotic rather than heavily calcified. While a cardiac computed tomography aortic valve calcium score of less than 1600 Agatston units (AU) typically makes severe aortic stenosis unlikely in men, cautious interpretation is required in patients who have conditions predisposing them to fibrotic stenosis without pronounced calcification, such as radiation-induced disease, bicuspid aortic valve, concomitant amyloidosis, and post-rheumatic or inflammatory diseases.

Question 45

A 72-year-old male is evaluated in the cardiology clinic for a routine follow-up. He reports no exertional dyspnea, angina, or syncope, and maintains a highly active lifestyle without limitations. Transthoracic echocardiography reveals a calcified, restricted aortic valve with an aortic valve area of 0.8 cm², a mean transvalvular gradient of 44 mmHg, and a peak aortic velocity of 4.1 m/s, consistent with severe aortic stenosis. The left ventricular ejection fraction is 55%. The physician decides to utilize advanced echocardiographic parameters to further risk-stratify this asymptomatic patient. Which of the following findings would specifically identify this patient as being at an increased risk for rapid clinical deterioration or premature mortality?

• ✓ A global longitudinal strain of -12%
• ○ A global longitudinal strain of -18%
• ○ A dimensionless velocity index greater than 0.25
• ○ Undetectable circulating levels of natriuretic peptides

Explanation. In patients with severe asymptomatic aortic stenosis, the assessment of global longitudinal strain provides crucial prognostic information regarding left ventricular function and extravalvular cardiac damage. A global longitudinal strain measurement demonstrating impaired myocardial deformation that is less negative than the threshold of -15% (such as -12%) identifies individuals who are at an increased risk for clinical deterioration or premature mortality.

Question 46

An 82-year-old male is evaluated for worsening dyspnea on exertion. Echocardiography demonstrates severe aortic stenosis (AS) with a calculated aortic valve area of 0.7 cm² and a mean transvalvular gradient of 46 mmHg. The echocardiogram also reveals severely thickened left ventricular walls out of proportion to the valvular disease. Transthyretin cardiac amyloidosis is suspected. Serum and urine immunofixation along with serum free light chain assays reveal no monoclonal protein, and a diphosphonate scintigraphy scan shows intense myocardial uptake, confirming the diagnosis of transthyretin cardiac amyloidosis. What is the most appropriate recommendation regarding the management of his severe AS?

• ✓ Proceed with valve intervention, as patients with concomitant severe aortic stenosis usually benefit from intervention despite the limited long-term prognosis of transthyretin cardiac amyloidosis.
• ○ Avoid valve intervention entirely due to the inherently limited long-term prognosis associated with transthyretin cardiac amyloidosis.
• ○ Postpone valve intervention until targeted amyloid-lowering therapies have objectively reversed the underlying restrictive cardiomyopathy.
• ○ Perform cardiopulmonary exercise testing and proceed with valve intervention only if the testing identifies deconditioning rather than cardiac limitation.

Explanation. Despite the limited long-term prognosis associated with cardiac transthyretin amyloidosis, patients with concomitant severe aortic stenosis generally experience clinical benefit from valve intervention.

Question 47

An 84-year-old woman with severe, symptomatic aortic stenosis is being evaluated for Transcatheter Aortic Valve Implantation (TAVI). She has a history of severe chronic kidney disease (estimated glomerular filtration rate of 20 mL/min/1.73 m²), making the preferred pre-procedural imaging tool relatively contraindicated. The heart team opts to use transoesophageal echocardiography (TOE) to assist with procedural planning. Which of the following is a known limitation of utilizing TOE instead of the preferred imaging modality in this scenario?

• ✓ It does not allow for the assessment of coronary and peripheral vascular anatomy.
• ○ It cannot be used to estimate the dimensions of the aortic root and ascending aorta.
• ○ It requires simultaneous left ventricular catheterization to confirm the transvalvular gradients.
• ○ It cannot evaluate the left ventricular outflow tract for the presence of calcification.

Explanation. Transoesophageal echocardiography (TOE) is operator-dependent and does not allow for the assessment of coronary and peripheral vascular anatomy, making it less comprehensive than cardiac computed tomography for determining the feasibility of vascular access during procedural planning.

Question 48

A 76-year-old man presents with progressive dyspnea on exertion and lower extremity edema over the past two months. His blood pressure is 155/92 mmHg. Transthoracic echocardiography demonstrates a severely calcified aortic valve with an aortic valve area of 0.6 cm², a mean transvalvular pressure gradient of 52 mmHg, and a left ventricular ejection fraction of 40%. He is otherwise functionally independent with an estimated life expectancy of greater than 5 years. What is the most appropriate approach to managing this patient?

• ✓ Initiate heart failure medical therapy, including a carefully titrated renin-angiotensin system blocker, and proceed to early valve intervention.
• ○ Initiate heart failure medical therapy to optimize his left ventricular ejection fraction and reassess for valve intervention in 6 months.
• ○ Proceed with early valve intervention but strictly avoid renin-angiotensin system blockers due to the risk of precipitating cardiogenic shock.
• ○ Defer valve intervention since the patient's depressed left ventricular ejection fraction reduces the expected benefits of the procedure.

Explanation. In patients with symptomatic severe aortic stenosis and heart failure, early intervention is strongly recommended when life expectancy exceeds one year, and the initiation of medical therapy or temporary improvement in symptoms should not delay this intervention. Furthermore, coexistent hypertension should be treated to avoid additional afterload, preferably using renin-angiotensin system blockers, requiring careful titration to avoid symptomatic hypotension.

Question 49

A 78-year-old male presents with progressive exertional dyspnea. Echocardiography reveals a left ventricular ejection fraction (LVEF) of 30%, a mean transaortic gradient of 25 mmHg, an aortic valve area of 0.8 cm², and a stroke volume index of 28 mL/m² (consistent with low flow). Low-dose dobutamine stress echocardiography shows an absence of flow reserve. A cardiac computed tomography (CCT) calcium score confirms the presence of severe aortic stenosis. He has no history of myocardial infarction or cardiomyopathy, and his reduced left ventricular function is determined to be predominantly caused by excessive afterload. Which of the following is the most appropriate approach and expectation regarding aortic valve intervention for this patient?

• ✓ Proceed with aortic valve intervention, as it improves clinical outcomes even in the absence of flow reserve, and left ventricular function will likely improve.
• ○ Defer aortic valve intervention in favor of guideline-directed medical therapy, as the absence of flow reserve indicates an unacceptably high mortality risk without clinical benefit.
• ○ Proceed with aortic valve intervention to relieve symptoms, though left ventricular function is unlikely to improve because the dysfunction is driven by excessive afterload.
• ○ Defer aortic valve intervention, as the presence of a low transaortic gradient and low flow definitively identifies pseudo-severe aortic stenosis requiring medical management.

Explanation. Proceeding with aortic valve intervention is the appropriate management because interventions improve left ventricular ejection fraction and clinical outcomes even in the absence of flow reserve, provided that severe aortic stenosis is confirmed by imaging modalities such as computed tomography calcium scoring. Furthermore, left ventricular function usually improves following intervention when the reduced ejection fraction is predominantly caused by excessive afterload rather than irreversible fibrosis.

Question 50

A 68-year-old man is evaluated for a newly discovered murmur. He is completely asymptomatic and maintains an active lifestyle, which is confirmed by a formal exercise stress test that demonstrates excellent exercise capacity with no symptom provocation. Transthoracic echocardiography reveals severe, high-gradient aortic stenosis (AS) with severe aortic valve calcification. His left ventricular ejection fraction (LVEF) is calculated at 53%. He is determined to be at low procedural risk. Which of the following is the most appropriate management strategy for this patient?

• ✓ Early aortic valve intervention
• ○ Clinical surveillance with a repeat echocardiogram in 12 months
• ○ Initiation of beta-blocker therapy and clinical review in 6 months
• ○ Deferral of intervention until the patient develops symptomatic exertional dyspnea

Explanation. Early aortic valve intervention is an appropriate management strategy in asymptomatic patients with severe high-gradient aortic stenosis who are at low procedural risk, and this approach is heavily reinforced when additional adverse prognostic features are present. An LVEF of less than 55% and severe valve calcification are established adverse prognostic features that favor proceeding with early intervention.

Question 51

A 72-year-old male presents to the cardiology clinic for a routine evaluation. Transthoracic echocardiography reveals asymptomatic severe aortic stenosis (AS). The patient strongly denies any exertional dyspnea, angina, or syncope, and maintains an active lifestyle. He is inquiring about the potential benefits of pre-emptive transcatheter aortic valve implantation (TAVI) and asks how early intervention compares to watchful waiting. What is the most accurate information to provide regarding the expected outcomes of early TAVI versus clinical surveillance?

• ○ Early TAVI provides a significant reduction in the isolated endpoints of stroke and all-cause mortality over a 5-year follow-up period.
• ○ Early TAVI reduces all-cause death and unplanned AS-related hospitalization specifically in patients who also have underlying myocardial fibrosis on imaging.
• ✓ Early TAVI significantly reduces a composite endpoint of all-cause mortality, stroke, or unplanned cardiovascular hospitalization, heavily driven by surveillance patients requiring intervention within 6 months.
• ○ Early TAVI completely prevents cardiovascular hospitalizations but is associated with a significantly higher 5-year risk of stroke compared to clinical surveillance.

Explanation. Pre-emptive transcatheter aortic valve implantation (TAVI) in asymptomatic severe aortic stenosis results in a 50% reduction in the primary composite endpoint of all-cause mortality, stroke, or unplanned hospitalization for cardiovascular causes. This reduction is primarily driven by patients in the clinical surveillance group who develop symptoms or adverse prognostic factors and require conversion to intervention within the first 6 months of follow-up.

Question 52

A 66-year-old man presents for a routine cardiology follow-up. He is completely asymptomatic and reports an active lifestyle, including jogging three miles daily without difficulty. An echocardiogram reveals an aortic valve area of 0.6 cm², a peak velocity of 4.8 m/s, and a mean transvalvular gradient of 58 mmHg, consistent with severe asymptomatic aortic stenosis. He has no other significant medical history and is deemed to be at low surgical risk. You discuss the potential benefits of early surgical aortic valve replacement versus clinical surveillance. Based on pooled data from randomized controlled trials, early intervention in this clinical scenario is associated with a significant reduction in which of the following?

• ✓ Unplanned heart failure hospitalization and stroke
• ○ All-cause mortality and cardiovascular mortality
• ○ All-cause mortality and stroke
• ○ Cardiovascular mortality and unplanned heart failure hospitalization

Explanation. Pooled data from randomized controlled trials demonstrates that early intervention in patients with severe asymptomatic aortic stenosis is associated with a significant reduction in unplanned cardiovascular or heart failure hospitalization and stroke, while not demonstrating a significant reduction in all-cause or cardiovascular mortality.

Question 53

A 72-year-old male with heart failure with reduced ejection fraction (HFrEF) and isolated moderate aortic stenosis (AS) is evaluated in the clinic. He has no indications for coronary artery bypass grafting (CABG), surgery of the ascending aorta, or other valve interventions. He inquires about the potential benefits of undergoing transcatheter aortic valve implantation (TAVI) for his moderate AS instead of clinical surveillance. Based on randomized trial data, what should the patient be counseled regarding the use of TAVI in this scenario?

• ✓ TAVI is associated with improved quality of life but no difference in hard clinical endpoints compared to clinical surveillance.
• ○ TAVI significantly reduces hard clinical endpoints compared to clinical surveillance but does not affect quality of life.
• ○ TAVI is strictly contraindicated in patients with HFrEF and moderate AS due to an increased risk of early mortality.
• ○ Clinical surveillance is associated with improved quality of life compared to TAVI due to the avoidance of procedural complications.

Explanation. In patients with moderate aortic stenosis and heart failure with reduced ejection fraction, randomized trial data comparing transcatheter aortic valve implantation to clinical surveillance demonstrated no differences with respect to hard clinical endpoints, but showed an improvement in quality of life for those undergoing the procedure.

Question 54

A 28-year-old woman with severe symptomatic aortic stenosis presents to the cardiology clinic to discuss treatment options. She is planning to become pregnant in the next few years and strongly prefers to avoid long-term anticoagulation. The heart team discusses the possibility of performing the Ross procedure at a highly specialized center. Which of the following represents an accurate characteristic of this surgical approach to guide her decision?

• ○ It utilizes a mechanical heart valve for the aortic position, making it the most durable option without the need for reintervention.
• ✓ It provides excellent long-term survival but is associated with procedural complexity and a need for reintervention in approximately 15% of patients within 15 years.
• ○ It avoids anticoagulation by utilizing a bovine bioprosthetic valve in the aortic position, which is typically preferred in patients under the age of 60.
• ○ It is indicated primarily for patients older than 65 years due to the limited long-term durability of the transplanted homograft.

Explanation. The Ross procedure involves replacing the aortic valve with the patient's own pulmonary autograft, combined with a homograft pulmonary valve replacement. It is a valuable surgical option for young patients with a prolonged life expectancy in whom anticoagulation is undesirable or contraindicated (such as women desiring pregnancy). While it offers excellent long-term survival when performed at centers with high expertise, it is associated with significant procedural complexity and requires reintervention in approximately 15% of patients within 15 years.

Question 55

An 81-year-old man presents to the emergency department with a hip fracture requiring urgent open reduction and internal fixation. Upon admission, he is found to be in acute decompensated heart failure with pulmonary edema. Echocardiography reveals severe aortic stenosis with an aortic valve area of 0.6 cm² and a mean transvalvular gradient of 50 mmHg. The multidisciplinary Heart Team determines that the patient requires urgent high-risk non-cardiac surgery for his fracture, but his decompensated severe aortic stenosis poses an unacceptably high perioperative risk. Immediate definitive transcatheter or surgical aortic valve replacement is deemed not feasible under the current acute circumstances. Which of the following is the most appropriate temporizing intervention for his valvular disease?

• ✓ Perform balloon aortic valvuloplasty prior to the non-cardiac surgery.
• ○ Proceed directly to the non-cardiac surgery with aggressive intravenous diuresis alone.
• ○ Perform urgent surgical aortic valve replacement simultaneously with the orthopedic surgery.
• ○ Defer the orthopedic surgery indefinitely and initiate palliative care.

Explanation. Balloon aortic valvuloplasty may be considered as a bridge to definitive therapy (transcatheter or surgical aortic valve replacement) in carefully selected patients with decompensated severe aortic stenosis, particularly those who require urgent high-risk non-cardiac surgery.

Question 56

A 72-year-old male presents with exertional dyspnea and angina. Echocardiography confirms symptomatic severe aortic stenosis with a tricuspid valve morphology, normal left ventricular ejection fraction, and a mean transvalvular gradient of 48 mmHg. Coronary angiography is unremarkable. He is evaluated by the Heart Team and deemed to be at low surgical risk. When counseling the patient regarding the choice between Transcatheter Aortic Valve Implantation (TAVI) and Surgical Aortic Valve Replacement (SAVR), which of the following statements regarding the expected outcomes at 1 year is most accurate?

• ✓ TAVI is associated with a lower risk of the composite of all-cause death and disabling stroke compared to SAVR at 1 year.
• ○ TAVI is associated with a similar risk of all-cause death and disabling stroke at 1 year, but superior outcomes at longer-term follow-up compared to SAVR.
• ○ SAVR is associated with a lower risk of all-cause death and disabling stroke at 1 year compared to TAVI in low-risk patients.
• ○ TAVI is associated with a higher risk of all-cause death, but a lower risk of disabling stroke at 1 year compared to SAVR.

Explanation. In patients at low surgical risk undergoing intervention for severe aortic stenosis, recent data and randomized clinical trials demonstrate an early benefit with TAVI, showing a risk reduction in all-cause death and disabling stroke at 1 year compared to SAVR.

Question 57

A 79-year-old man with severe, symptomatic aortic stenosis is evaluated by the structural heart team. He has a history of mild chronic kidney disease and hypertension. He is deemed a suitable candidate for both transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). During shared decision-making, the patient asks about the specific procedural risks and expected recovery for each approach. Which of the following complication profiles accurately reflects the comparison between TAVI and SAVR?

• ○ TAVI carries a higher risk of severe bleeding, acute kidney injury, and new-onset atrial fibrillation compared to SAVR.
• ✓ TAVI carries a higher risk of vascular complications, paravalvular leak, and new pacemaker implantation, whereas SAVR carries a higher risk of acute kidney injury and new-onset atrial fibrillation.
• ○ SAVR carries a higher risk of vascular complications and paravalvular leak, whereas TAVI carries a higher risk of severe bleeding and acute kidney injury.
• ○ SAVR is associated with quicker recoveries and shorter hospital stays, but carries a higher risk of paravalvular leak compared to TAVI.

Explanation. Transcatheter aortic valve implantation (TAVI) is consistently associated with higher rates of vascular complications, paravalvular leak, and new pacemaker implantations (particularly with self-expanding valves). Surgical aortic valve replacement (SAVR) is associated with a higher frequency of severe bleeding, acute kidney injury, and new-onset atrial fibrillation.

Question 58

A 65-year-old man and an 82-year-old man both present with severe, symptomatic aortic stenosis (AS). Both undergo successful valve replacement therapies without immediate procedural complications. When discussing long-term prognostic expectations with these patients and their families, which of the following is the most accurate statement regarding their post-procedural life expectancy compared to the age-matched general population?

• ○ Both patients will have a post-procedural life expectancy that normalizes to match the age-matched general population.
• ✓ The 65-year-old patient will have a life expectancy lower than the general population despite valve replacement, whereas the 82-year-old patient's life expectancy will almost normalize.
• ○ The 82-year-old patient will have a life expectancy significantly lower than the general population, whereas the 65-year-old patient's life expectancy will completely normalize.
• ○ Both patients will have a significantly lower life expectancy compared to the general population due to irreversible myocardial damage.

Explanation. Younger patients with aortic stenosis have a lower life expectancy than the general population despite undergoing valve replacement, whereas life expectancy almost normalizes after treatment in older cohorts.

Question 59

A 79-year-old female presents with progressive exertional dyspnea and an episode of syncope. Echocardiography confirms severe, high-gradient aortic stenosis. A pre-procedural computed tomography scan is performed to guide the Heart Team in choosing between transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). Which of the following anatomical findings most strongly favors TAVI over SAVR?

• ✓ Porcelain aorta
• ○ Cusp height greater than coronary height combined with shallow sinuses of Valsalva
• ○ Excessive, bulky calcification extending into the left ventricular outflow tract
• ○ Aortic annular dimensions that lie outside the sizing recommendations for transcatheter devices

Explanation. Anatomical findings such as a porcelain aorta, severe chest deformation, or intact grafts post-coronary artery bypass grafting strongly favor transcatheter aortic valve implantation.

Question 60

A 64-year-old male with a history of hypertension presents with new-onset exertional angina and dyspnea. Echocardiography and cardiac computed tomography demonstrate severe aortic stenosis with a bicuspid aortic valve (BAV) and an ascending aorta diameter of 48 mm. The valve morphology features heavy cusp calcification and a dense, calcified raphe. His estimated surgical risk is low. What is the most appropriate intervention for this patient and the rationale based on his specific valve morphology?

• ✓ Surgical aortic valve replacement (SAVR), because heavy cusp calcification with a calcified raphe increases the risk of aortic root injury, paravalvular leak, and mortality during transcatheter aortic valve implantation (TAVI).
• ○ Transcatheter aortic valve implantation (TAVI), because BAV patients were the primary cohort showing a significant mortality benefit in landmark trials comparing TAVI with SAVR.
• ○ Transcatheter aortic valve implantation (TAVI), because the presence of a calcified raphe reduces the risk of paravalvular leak by providing a stable landing zone for the transcatheter prosthesis.
• ○ Surgical aortic valve replacement (SAVR), because transcatheter approaches are absolutely contraindicated in all patients with bicuspid aortic valve anatomy due to the elliptical annular shape.

Explanation. Surgical aortic valve replacement (SAVR) is the primary mode of treatment for stenotic bicuspid aortic valves, particularly in relatively young patients, those with coexistent aortopathy, or those with unfavorable valve morphology. The presence of heavy cusp calcification in conjunction with a calcified raphe is a specific anatomical feature that increases the risk of aortic root injury, paravalvular leak, and mortality when undergoing transcatheter aortic valve implantation (TAVI), making SAVR the preferred and safest intervention for this patient.

Question 61

A 75-year-old female with symptomatic severe aortic stenosis is evaluated for intervention. Her echocardiogram and cardiac computed tomography demonstrate a small aortic annulus in relation to her body stature, placing her at increased risk for prosthesis-patient mismatch. The Heart Team discusses the optimal mode of intervention and prosthesis type. Which of the following is the most accurate consideration regarding valve selection and procedural approach for this patient?

• ○ Annular enlargement during surgical aortic valve replacement reduces prosthesis-patient mismatch and is associated with a decreased risk of operative mortality.
• ✓ Utilization of a transcatheter heart valve with a supra-annular design reduces the risk of prosthesis-patient mismatch, although randomized long-term data on valve durability are pending.
• ○ Surgical transcatheter heart valve explantation followed by surgical aortic valve replacement is associated with a low early mortality rate if future reintervention is needed.
• ○ Annular enlargement during surgical aortic valve replacement is a technically simple procedure that should be routinely performed across all surgical centers for patients with a small annulus.

Explanation. In patients with a small aortic annulus, utilizing a transcatheter heart valve with a supra-annular design reduces the risk of prosthesis-patient mismatch, though randomized long-term data evaluating its impact on clinical outcomes and valve durability are currently pending.

Question 62

An 82-year-old man with a history of a surgical aortic valve replacement (SAVR) 12 years ago presents with severe symptomatic bioprosthetic valve degeneration. He is deemed high risk for a redo SAVR, and the multidisciplinary heart team recommends a transcatheter aortic valve-in-surgical aortic valve (TAV-in-SAV) procedure. During pre-procedural planning, the structural interventionalist evaluates the patient's computed tomography (CT) scan to assess the risk of procedural complications. Which of the following anatomical findings would most significantly increase the risk of indirect coronary flow obstruction (sinus sequestration) following the planned TAV-in-SAV procedure?

• ○ Deep sinuses of Valsalva combined with a dilated ascending aorta
• ✓ A narrow ascending aorta where the anticipated neo-skirt reaches the sinotubular junction
• ○ A large aortic annulus diameter accompanied by a wide sinotubular junction
• ○ A heavily calcified aortic arch with a tortuous descending thoracic aorta

Explanation. Valve-in-valve implantation immobilizes the leaflets of the failed prosthesis in an open position, creating a covered tube known as a neo-skirt. This structural change may cause indirect coronary flow obstruction as a result of sinus sequestration particularly when the ascending aorta is narrow and the neo-skirt reaches the sinotubular junction.

Question 63

A 74-year-old man presents with progressive dyspnea on exertion. He underwent surgical aortic valve replacement (SAVR) 11 years ago with a stentless bioprosthesis. Echocardiography reveals severe structural valve deterioration with a mean gradient of 50 mmHg and an aortic valve area of 0.7 cm2. A dedicated cardiac computed tomography (CT) scan indicates a high risk of coronary obstruction if a transcatheter valve-in-valve procedure is performed. His calculated surgical risk is elevated (Society of Thoracic Surgeons Predicted Risk of Mortality 6%). What is the most appropriate primary management strategy for this patient?

• ✓ Redo surgical aortic valve replacement (SAVR)
• ○ Valve-in-valve transcatheter aortic valve implantation (TAVI) using a supra-annular valve
• ○ Valve-in-valve transcatheter aortic valve implantation (TAVI) using a balloon-expandable intra-annular valve
• ○ Medical therapy alone, as the elevated surgical risk precludes redo SAVR and the coronary obstruction risk precludes TAVI

Explanation. In patients who require a reintervention due to dysfunction of a surgical or transcatheter bioprosthesis and are at an increased risk of severe patient-prosthesis mismatch or coronary obstruction—such as those with a previous stentless surgical valve—redo surgical aortic valve replacement (SAVR) is the preferable approach despite an increased surgical risk.

Question 64

An 81-year-old female presents with progressive exertional dyspnea and syncope. Echocardiography reveals symptomatic severe aortic stenosis (AS) with a peak transvalvular velocity (Vmax) of 4.5 m/s. She is evaluated for a valve replacement and is determined to be a suitable candidate for a bioprosthesis. The multidisciplinary Heart Team convenes to select the most appropriate mode of intervention. Which of the following encompasses the core factors that must be integrated into their decision-making process?

• ✓ Procedural risk based on anatomical characteristics and comorbidities, expected outcomes, lifetime management considerations, and patient preference
• ○ Procedural risk based exclusively on the European System for Cardiac Operative Risk Evaluation (EuroSCORE), left ventricular ejection fraction (LVEF), and stroke volume index (SVi)
• ○ Patient preference, chronological age, and the isolated presence of a bicuspid aortic valve (BAV)
• ○ The absolute requirement for concomitant coronary artery bypass grafting (CABG) or ascending aortic surgery irrespective of expected outcomes

Explanation. For candidates receiving a bioprosthesis, selecting the most appropriate mode of intervention requires a comprehensive evaluation by the Heart Team that must integrate procedural risk—which is based on the patient's anatomical characteristics and comorbidities—along with expected outcomes, considerations for lifetime management, and the individual patient's preference.

Question 65

A 74-year-old woman is referred for evaluation of exertional dyspnea. Transthoracic echocardiography demonstrates a small calculated aortic valve area (AVA) of 0.8 cm² but a low mean transaortic gradient of 30 mmHg, despite a preserved left ventricular ejection fraction (LVEF) of 55%. The cardiologist is considering a diagnosis of severe aortic stenosis (AS). Before confirming severe AS in this scenario, which of the following alternative explanations for these specific echocardiographic findings must be carefully excluded?

• ○ Severe concomitant aortic regurgitation, high cardiac output states, and hyperthyroidism
• ○ Atrial septal defect, severe pulmonary hypertension, and isolated right ventricular failure
• ✓ Measurement errors, uncontrolled blood pressure, and conditions lowering the stroke volume
• ○ Ascending aortic aneurysm, bicuspid aortic valve, and a subaortic membrane

Explanation. In patients presenting with echocardiographic findings of a small aortic valve area (AVA) but a low mean gradient despite a preserved left ventricular ejection fraction (LVEF), alternative explanations such as measurement errors, uncontrolled blood pressure, and other conditions that lower the stroke volume are frequent and must be carefully excluded before establishing a definitive diagnosis of severe aortic stenosis.

Question 66

A 74-year-old male presents for a routine cardiovascular evaluation. He is completely asymptomatic and maintains an active lifestyle, including playing golf twice a week without exertional dyspnea, chest pain, or lightheadedness. A transthoracic echocardiogram demonstrates moderate degenerative aortic stenosis (AS) with significant valve calcification and a normal left ventricular ejection fraction (LVEF) of 62%. What is the most appropriate interval for clinical and echocardiographic follow-up for this patient?

• ○ At least every 6 months
• ✓ At least annually
• ○ Every 2 to 3 years
• ○ Every 4 to 5 years

Explanation. Patients with moderate degenerative aortic stenosis, particularly those with significant valve calcification, face an accelerated rate of disease progression and a worse prognosis than historically considered, necessitating clinical and echocardiographic re-evaluation at least annually.

Question 67

A 74-year-old male successfully undergoes surgical aortic valve replacement with a bioprosthesis for severe symptomatic aortic stenosis. His postoperative course is uncomplicated, and he is preparing to transition to a cardiac rehabilitation program to improve his activities of daily living and 6-minute walking distance. As you outline his long-term outpatient management plan, which of the following represents the most appropriate routine echocardiographic follow-up strategy for this patient?

• ✓ Perform a baseline echocardiogram within the first weeks after replacement, followed by annual echocardiographic examinations.
• ○ Perform a baseline echocardiogram at 3 months, followed by routine echocardiographic evaluations every 2 to 3 years.
• ○ Perform a baseline echocardiogram at 6 months, followed by annual echocardiograms starting 5 years post-operatively.
• ○ Perform an echocardiogram exclusively when the patient develops new clinical symptoms or signs suggestive of valve dysfunction.

Explanation. After valve intervention, an early echocardiographic examination within the first weeks after valve replacement is indicated to document the baseline prosthetic valve function. Subsequently, patients who have received a bioprosthesis require routine cardiological evaluations and echocardiographic examinations on an annual basis to monitor ongoing valve performance.

Question 68

A 45-year-old woman with a history of Barlow's disease presents for a routine cardiology follow-up. She reports experiencing recurrent palpitations over the past six months. A 24-hour Holter monitor demonstrates a high burden of premature ventricular complexes and several runs of non-sustained ventricular tachycardia. A transthoracic echocardiogram confirms myxomatous alterations of the mitral valve with moderate primary mitral regurgitation and mitral annular disjunction. The patient's left ventricular size and systolic function are normal. Which of the following pathophysiological mechanisms is most likely responsible for the development of her ventricular arrhythmias?

• ○ Severe left ventricular volume overload resulting in eccentric hypertrophy and diffuse subendocardial fibrosis.
• ✓ Atrial displacement of the posterior mitral valve leaflet hinge point causing increased tension and local fibrosis of the papillary muscles and posterobasal myocardium.
• ○ Acute infectious vegetations causing local tissue destruction and micro-abscess formation within the conduction system.
• ○ Fibroelastic deficiency leading to isolated chordal rupture and subsequent anterior papillary muscle ischemia.

Explanation. In patients with Barlow's disease and mitral annular disjunction, ventricular arrhythmias are driven by anatomical and mechanical alterations rather than the severity of the mitral regurgitation itself. Atrial displacement of the posterior mitral valve leaflet hinge point causes excessive mobility of the valvular apparatus. This excessive mobility increases mechanical tension on the papillary muscles and the posterobasal myocardium, which eventually induces local myocardial fibrosis that serves as an arrhythmogenic substrate for ventricular arrhythmias.

Question 69

A 62-year-old male presents with progressive shortness of breath when climbing stairs. Physical examination reveals a holosystolic murmur at the cardiac apex. A resting transthoracic echocardiogram (TTE) demonstrates structurally normal left and right ventricles, normal biatrial dimensions, and mild-to-moderate mitral regurgitation (MR). His resting pulmonary artery systolic pressure is estimated at 28 mmHg. Given that his severe exertional symptoms are discordant with the resting MR severity, what is the most appropriate next step in his echocardiographic evaluation?

• ○ Perform a resting transesophageal echocardiogram (TOE) to better assess leaflet morphology.
• ✓ Proceed with exercise echocardiography to evaluate dynamic changes in the regurgitant jet and pulmonary pressures.
• ○ Schedule a three-dimensional transesophageal echocardiogram (3D TOE) to plan for transcatheter repair.
• ○ Re-evaluate resting TTE with altered color flow settings to intentionally overestimate the MR severity.

Explanation. Exercise echocardiography evaluates dynamic changes in the regurgitant jet and pulmonary pressures during peak exercise, making it a highly useful modality in patients who present with discordant symptoms and regurgitation severity at rest.

Question 70

A 60-year-old asymptomatic man is evaluated for a holosystolic murmur at the apex. Echocardiography reveals severe primary mitral regurgitation (PMR) due to a flail posterior leaflet, with a vena contracta of 8 mm and an effective regurgitant orifice area (EROA) of 45 mm^2. His left ventricular ejection fraction is 65%. Which of the following additional echocardiographic findings is recognized as an important marker of worse prognosis that should strongly influence the timing of intervention?

• ✓ Resting pulmonary artery pressure of 55 mmHg
• ○ Left atrial volume index of 45 mL/m^2
• ○ Mild secondary tricuspid regurgitation
• ○ Left ventricular end-diastolic diameter of 48 mm

Explanation. In asymptomatic patients with severe primary mitral regurgitation, elevated pulmonary pressures greater than 50 mmHg at rest serve as an important marker of worse prognosis and should be directly considered when determining the optimal timing for intervention.

Question 71

A 42-year-old woman with a history of Barlow's disease and severe primary mitral regurgitation presents to the cardiology clinic complaining of occasional palpitations. Transthoracic echocardiography reveals severe bileaflet mitral valve prolapse with mitral annular disjunction. To further evaluate her condition and precise ventricular volumes, cardiac magnetic resonance (CMR) imaging is performed. The CMR study confirms the presence of mitral annular disjunction and additionally demonstrates patchy late gadolinium enhancement in the papillary muscles and the inferobasal left ventricular wall. What does the presence of this specific CMR finding indicate in this patient?

• ✓ High risk for ventricular arrhythmias and sudden cardiac death
• ○ Impending left ventricular systolic dysfunction requiring immediate surgery
• ○ Need for pre-procedural planning for transcatheter mitral valve implantation
• ○ Increased likelihood of long-term mortality regardless of surgical intervention

Explanation. In patients with Barlow's disease and mitral annular disjunction, the presence of myocardial fibrosis detected by cardiac magnetic resonance imaging is associated with an increased risk of ventricular arrhythmias and sudden cardiac death.

Question 72

A 78-year-old female presents with progressive dyspnea on exertion and is classified with New York Heart Association class III heart failure symptoms. Transthoracic echocardiography demonstrates severe mitral regurgitation and extensive mitral annular calcification. The multidisciplinary team is evaluating her for potential surgical or transcatheter mitral valve intervention. Which of the following imaging modalities is most appropriate to evaluate the extent and distribution of her calcifications for detailed procedural planning?

• ✓ Cardiac computed tomography
• ○ Cardiac magnetic resonance imaging
• ○ Three-dimensional transesophageal echocardiography
• ○ Cardiac fluoroscopy

Explanation. Cardiac computed tomography possesses exceptionally high sensitivity for the detection of calcifications, making it instrumental for accurate surgical and transcatheter procedural planning in patients with mitral annular calcification.

Question 73

A 64-year-old man presents to the emergency department with a sudden onset of severe dyspnea. Echocardiography reveals acute severe primary mitral regurgitation (PMR) secondary to a degenerative chordal rupture. His blood pressure is 150/90 mmHg, heart rate is 112 beats per minute, and oxygen saturation is 88% on room air. The patient is scheduled for an urgent intervention. In addition to intravenous diuretics, which of the following is the most appropriate therapy to serve as a bridge to his intervention?

• ✓ Administration of sodium nitroprusside
• ○ Implantation of an intra-aortic balloon pump
• ○ Initiation of oral lisinopril
• ○ Administration of intravenous metoprolol

Explanation. Afterload reduction with sodium nitroprusside is used as an effective bridge to intervention in patients with acute severe primary mitral regurgitation who present without signs of hypotension.

Question 74

A 65-year-old male presents with progressively worsening dyspnea on exertion and is found to have severe primary mitral regurgitation (PMR) secondary to rheumatic heart disease. Echocardiography reveals extensive annular and leaflet calcifications. He is referred to an experienced Heart Valve Centre for surgical evaluation. Intraoperatively, the surgical team determines that an optimal and durable mitral valve (MV) repair is not feasible due to the extensive leaflet destruction and calcification. Which of the following is the most appropriate next step in surgical management?

• ✓ Mitral valve replacement with preservation of the subvalvular apparatus
• ○ Mitral valve replacement with complete excision of the subvalvular apparatus to ensure secure seating of the prosthesis
• ○ Proceed with a partial mitral valve repair without an annuloplasty ring
• ○ Abort the procedure and evaluate the patient for transcatheter edge-to-edge repair

Explanation. When mitral valve repair is not feasible in patients undergoing surgery for severe primary mitral regurgitation, the indicated procedure is valve replacement with preservation of the subvalvular apparatus.

Question 75

An 82-year-old female with severe, symptomatic chronic primary mitral regurgitation (PMR) presents for evaluation. Her past medical history is significant for severe chronic obstructive pulmonary disease, frailty, and chronic kidney disease, rendering her a prohibitive surgical risk. Echocardiography demonstrates severe PMR with complex mitral valve anatomy that is deemed unsuitable for transcatheter edge-to-edge repair (TEER) by the Heart Team. Transcatheter mitral valve implantation (TMVI) is proposed as an alternative. When counseling the patient about the potential procedural risks and limitations of TMVI, which of the following should be highlighted as major drawbacks of current TMVI systems?

• ✓ Limited availability, high screening failure rate, and risk of left ventricular outflow tract (LVOT) obstruction and valve thrombosis
• ○ High rate of permanent pacemaker implantation, coronary artery obstruction, and paravalvular leak
• ○ Risk of device embolization, significant residual mitral regurgitation, and need for lifelong triple antithrombotic therapy
• ○ High incidence of right ventricular failure, persistent iatrogenic atrial septal defect, and early structural valve deterioration

Explanation. TMVI is a highly effective alternative for abolishing mitral regurgitation in selected high-risk patients, particularly those with complex mitral valve anatomy that is unsuitable for TEER. However, the use of current TMVI systems is limited by major drawbacks including limited availability, high screening failure rates, and the risk of left ventricular outflow tract (LVOT) obstruction and valve thrombosis.

Question 76

A 58-year-old male is evaluated for severe primary mitral regurgitation due to myxomatous degeneration (mitral valve prolapse). He is asymptomatic and exercises regularly without limitation. Transthoracic echocardiography demonstrates a left ventricular ejection fraction of 64% and a left ventricular end-systolic diameter of 36 mm. Assuming a low surgical risk and a high expected probability of durable mitral valve repair, which of the following additional findings should prompt referral for early corrective surgery?

• ✓ Left atrial volume index of 65 mL/m²
• ○ Resting systolic pulmonary artery pressure of 45 mmHg
• ○ Left atrial diameter of 50 mm
• ○ Concomitant mild secondary tricuspid regurgitation

Explanation. The presence of marked left atrial dilatation, defined as a left atrial volume index of 60 mL/m² or greater, is associated with a worse long-term prognosis irrespective of left ventricular function after corrective surgery and should prompt surgical referral in low-risk patients when a high probability of successful valve repair is expected.

Question 77

A 56-year-old male presents for planned surgical repair of severe primary mitral valve (MV) regurgitation. He works in a physically demanding job and is anxious about his postoperative recovery time. He asks his cardiologist about the potential benefits of a minimally invasive MV surgery via mini-thoracotomy compared to a conventional sternotomy approach, specifically regarding his return to baseline physical function. Which of the following accurately describes the anticipated physical recovery timeline associated with the mini-thoracotomy approach?

• ✓ Improved physical activity compared to conventional surgery within the first 6 weeks, with the difference disappearing at 12 weeks.
• ○ Improved physical activity that becomes apparent only after 12 weeks of postoperative cardiac rehabilitation.
• ○ Sustained improvement in physical activity compared to conventional surgery that persists for at least 1 year.
• ○ Similar physical activity levels in the first 6 weeks, with a significant decline at 12 weeks due to delayed incisional pain.

Explanation. Minimally invasive mitral valve surgery via mini-thoracotomy is associated with a shorter hospital stay and improved physical activity during the early postoperative period, specifically within the first 6 weeks after surgery, facilitating accelerated early recovery. This comparative advantage in physical activity over conventional surgical approaches equalizes over time and disappears at the 12-week mark.

Question 78

A 52-year-old male presents for a routine physical examination. A grade 3/6 holosystolic murmur radiating to the axilla is auscultated. He is completely asymptomatic and regularly plays competitive tennis without any dyspnea or fatigue. A comprehensive transthoracic echocardiogram reveals severe mitral regurgitation (MR) due to myxomatous degeneration with a flail P2 scallop. His left ventricular ejection fraction is 62%, and his left ventricular end-systolic dimension is 38 mm. A formal treadmill stress test confirms excellent, age-appropriate functional capacity without symptom provocation. Which of the following is the most appropriate follow-up strategy for this patient?

• ✓ Clinical and echocardiographic follow-up twice per year.
• ○ Clinical evaluation yearly and echocardiography every 1 to 2 years.
• ○ Clinical and echocardiographic follow-up every 2 to 3 years.
• ○ Referral for immediate surgical mitral valve replacement.

Explanation. Asymptomatic patients with severe mitral regurgitation who do not fulfill the criteria for an intervention and have documented preserved exercise capacity should be managed with a watchful waiting strategy that consists of both clinical and echocardiographic follow-up twice per year.

Question 79

An 81-year-old man with a history of surgical mitral valve repair utilizing a ring annuloplasty 7 years ago presents with worsening dyspnea (New York Heart Association class III). Transesophageal echocardiography reveals severe recurrent mitral regurgitation. Due to severe chronic obstructive pulmonary disease and frailty, he is deemed at high surgical risk. The Heart Team evaluates him for a transcatheter mitral valve-in-ring procedure. Which of the following complications is a major concern specifically associated with this intervention that requires careful pre-procedural assessment?

• ✓ Left ventricular outflow tract obstruction
• ○ Complete atrioventricular block requiring permanent pacing
• ○ Coronary sinus rupture or thrombosis
• ○ Embolization of the surgical annuloplasty ring

Explanation. Transcatheter alternatives for recurrent mitral regurgitation after surgical ring annuloplasty, such as mitral valve-in-ring procedures, are reserved for selected high-risk patients due to the specific risk of left ventricular outflow tract (LVOT) obstruction, as well as paravalvular leak. Careful pre-procedural assessment is required to evaluate the neo-LVOT and mitigate the risk of obstruction before proceeding with a transcatheter valve-in-ring intervention.

Question 80

A 72-year-old woman with a history of heart failure with preserved ejection fraction and long-standing atrial fibrillation presents to the clinic with worsening exertional dyspnea. Echocardiography demonstrates severe secondary mitral regurgitation with grossly normal-appearing mitral valve leaflets. Which of the following morphological characteristics is most likely the primary mechanism for her mitral regurgitation?

• ○ Leaflet tethering and restricted motion combined with annular dilation
• ✓ Annulus enlargement and flattening leading to planar coaptation
• ○ Systolic anterior motion of the anterior mitral valve leaflet
• ○ Elongation and chordal rupture leading to a flail posterior leaflet

Explanation. The patient's clinical profile, including age over 65 years, female sex, long-standing atrial fibrillation, and heart failure with preserved ejection fraction, is characteristic of atrial secondary mitral regurgitation. From a morphological standpoint, atrial secondary mitral regurgitation is predominantly driven by pure mitral annular dilation, specifically characterized by annulus enlargement and flattening that leads to planar coaptation.

Question 81

A 72-year-old woman presents for evaluation of progressive exertional dyspnea. After optimization of guideline-directed medical therapy, she is currently euvolemic and normotensive. Transthoracic echocardiography reveals secondary mitral regurgitation (SMR) with an effective regurgitant orifice area (EROA) of 34 mm² and a regurgitant volume (RVol) of 48 mL. The cardiologist is determining whether the etiology of the SMR is primarily atrial or ventricular. Which of the following echocardiographic findings is most characteristic of atrial secondary mitral regurgitation?

• ○ Left ventricular ejection fraction (LVEF) of 42% with restrictive mitral leaflet motion and tethering
• ✓ Left ventricular ejection fraction (LVEF) of 55% with no regional wall motion abnormalities, a mildly dilated left ventricle without leaflet tethering, and a left atrial volume index of 45 mL/m²
• ○ Left ventricular ejection fraction (LVEF) of 35% with a central regurgitant jet and a severely dilated left ventricle
• ○ Left ventricular ejection fraction (LVEF) of 40% with an akinetic inferior wall and significant leaflet tethering

Explanation. Atrial secondary mitral regurgitation is characterized by a preserved left ventricular ejection fraction (LVEF ≥50%) without regional wall motion abnormalities, no or mildly dilated left ventricular cavity without leaflet tethering, and an enlarged left atrium (left atrial volume index >34 mL/m²).

Question 82

A 74-year-old woman with a history of permanent atrial fibrillation and heart failure with preserved ejection fraction (HFpEF) presents with worsening exertional dyspnea. Auscultation reveals a holosystolic murmur at the apex. Transthoracic echocardiography is performed to evaluate the etiology of her mitral regurgitation. Which of the following sets of echocardiographic findings is most characteristic of atrial secondary mitral regurgitation in this patient?

• ✓ Left ventricular ejection fraction (LVEF) 55%, left ventricular end-diastolic dimension (LVEDD) 48 mm, mitral annulus anteroposterior diameter 38 mm, and normal leaflet motion with a central regurgitant jet.
• ○ Left ventricular ejection fraction (LVEF) 35%, left ventricular end-diastolic dimension (LVEDD) 65 mm, mitral annulus anteroposterior diameter 32 mm, and restricted systolic leaflet motion with apical tethering.
• ○ Left ventricular ejection fraction (LVEF) 60%, left ventricular end-diastolic dimension (LVEDD) 45 mm, mitral annulus anteroposterior diameter 30 mm, and systolic billowing of the posterior leaflet into the left atrium with an eccentric regurgitant jet.
• ○ Left ventricular ejection fraction (LVEF) 45%, left ventricular end-diastolic dimension (LVEDD) 58 mm, regional wall motion abnormalities in the inferior wall, and restricted posterior leaflet motion.

Explanation. Atrial secondary mitral regurgitation is defined by the presence of a preserved left ventricular ejection fraction (≥50%) without regional wall motion abnormalities or leaflet tethering, an absent or mildly dilated left ventricular cavity (left ventricular end-diastolic dimension of <56 mm in women), and mitral annulus dilatation (anteroposterior diameter >35 mm). Echocardiography typically demonstrates normal leaflet motion with planar coaptation, normal leaflet morphology, and a central regurgitant jet.

Question 83

A 65-year-old man with a history of an anterior myocardial infarction presents with progressive dyspnea on exertion and fatigue, consistent with New York Heart Association (NYHA) class III symptoms. Echocardiography reveals a dilated left ventricle with a left ventricular ejection fraction (LVEF) of 30% and severe secondary mitral regurgitation (SMR) due to tethering of the leaflets. His electrocardiogram (ECG) shows normal sinus rhythm with a narrow QRS duration of 90 ms. His current medications include low-dose lisinopril and carvedilol. Blood pressure is 115/75 mmHg, and renal function and potassium levels are within normal limits. What is the most appropriate next step in the management of this patient?

• ○ Immediate transcatheter edge-to-edge repair (TEER) of the mitral valve.
• ○ Immediate surgical mitral valve repair with an undersized annuloplasty ring.
• ✓ Optimization of guideline-directed medical therapy (GDMT) with rapid up-titration, followed by reassessment of SMR severity in 1 to 3 months.
• ○ Implantation of a cardiac resynchronization therapy (CRT) device followed by immediate transcatheter mitral valve repair.

Explanation. In patients with ventricular secondary mitral regurgitation, optimization of guideline-directed medical therapy for heart failure—including maximum tolerated doses of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or angiotensin receptor/neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter 2 inhibitors—is required prior to any mitral valve intervention. Rapid up-titration of these medications within 6 weeks can lead to an improvement in mitral regurgitation severity in a significant proportion of patients after 1 to 3 months.

Question 84

A 68-year-old female presents with worsening dyspnea on minimal exertion, consistent with New York Heart Association (NYHA) class III symptoms. She has a history of non-ischemic dilated cardiomyopathy without relevant coronary artery disease (CAD). Echocardiography reveals a left ventricular ejection fraction of 28% and severe ventricular secondary mitral regurgitation (SMR). She has been on maximally tolerated guideline-directed medical therapy (GDMT) for heart failure (HF) for two years and underwent cardiac resynchronization therapy (CRT) one year ago. A multidisciplinary Heart Team evaluates her case, deeming her at high surgical risk but confirming she fulfills echocardiographic criteria for percutaneous intervention. Which of the following therapies has been shown to reduce recurrent HF hospitalizations and all-cause mortality compared to continued GDMT alone in this specific patient population?

• ✓ Mitral transcatheter edge-to-edge repair (M-TEER)
• ○ Surgical mitral valve replacement with chordal preservation
• ○ Continuous intravenous milrinone infusion
• ○ Surgical restrictive mitral annuloplasty

Explanation. Mitral transcatheter edge-to-edge repair (M-TEER) safely reduces recurrent heart failure hospitalizations and all-cause mortality at 2 and 5 years of follow-up compared with optimized guideline-directed medical therapy alone in patients with ventricular secondary mitral regurgitation without relevant coronary artery disease who remain symptomatic despite adequate medical and device therapy.

Question 85

A 72-year-old man with non-ischemic cardiomyopathy and a left ventricular ejection fraction of 30% presents to the clinic. He is on maximally tolerated guideline-directed medical therapy but continues to experience severe dyspnea on exertion. An echocardiogram reveals severe secondary (functional) mitral regurgitation. The heart team considers him a candidate for transcatheter edge-to-edge repair (TEER). When discussing the anticipated benefits of this intervention based on a recent study-level meta-analysis of major randomized controlled trials, which of the following outcomes at 24 months is most accurate?

• ✓ A significant reduction in heart failure rehospitalization, with no statistically significant difference in cardiovascular death or death from any cause.
• ○ A significant reduction in both heart failure rehospitalization and cardiovascular death.
• ○ No significant difference in the composite of death and all-cause hospitalizations.
• ○ A significant reduction in death from any cause without a significant reduction in heart failure rehospitalizations.

Explanation. A study-level meta-analysis of major trials evaluating transcatheter edge-to-edge repair in patients with severe secondary mitral regurgitation demonstrated a significant reduction in heart failure rehospitalization and the composite of death and all-cause hospitalizations at 24 months, but no statistically significant difference in death from any cause or cardiovascular death.

Question 86

A 72-year-old male presents with persistent dyspnea (New York Heart Association class III) two months after suffering a myocardial infarction (MI). Echocardiography reveals persistent severe secondary mitral regurgitation (SMR) of ventricular origin, and anatomical assessment indicates the valve is suitable for percutaneous intervention. He is currently on low doses of guideline-directed medical therapy (GDMT) for heart failure, but multiple attempts to up-titrate his medications have been unsuccessful due to symptomatic hypotension. Which of the following interventions is supported by observational evidence to improve this patient's symptoms and potentially facilitate the successful up-titration of his medical therapy?

• ✓ Transcatheter edge-to-edge repair (TEER)
• ○ Surgical mitral valve replacement with a bioprosthesis
• ○ Percutaneous balloon mitral valvuloplasty
• ○ Surgical mitral valve repair with a rigid annuloplasty ring

Explanation. Transcatheter edge-to-edge repair (TEER) improves symptoms, functional capacity, and quality of life in patients with severe ventricular secondary mitral regurgitation, including those with a recent myocardial infarction and persistent severe regurgitation. Furthermore, it is particularly useful in patients who cannot initially tolerate optimal heart failure medications, as the hemodynamic improvement provided by the procedure can help facilitate the subsequent up-titration of guideline-directed medical therapy (GDMT).

Question 87

A 65-year-old man with ischemic cardiomyopathy and symptomatic secondary mitral regurgitation is enrolled in a clinical trial to evaluate a transcatheter indirect annuloplasty device implanted into the coronary sinus. The investigators are evaluating the efficacy of the device compared to a sham procedure. What are the expected primary findings regarding mitral regurgitant volume (RVol) and quality of life?

• ✓ A modest reduction in mitral RVol with no significant effect on quality of life.
• ○ A substantial reduction in mitral RVol with marked improvement in quality of life.
• ○ A modest reduction in mitral RVol with significant improvement in quality of life.
• ○ No significant reduction in mitral RVol with significant improvement in quality of life.

Explanation. Transcatheter implantation of an indirect annuloplasty device into the coronary sinus results in a modest reduction in secondary mitral regurgitation (approximately a 22.4% decrease in mitral regurgitant volume) and demonstrates no significant effect on quality of life in sham-controlled randomized controlled trials.

Question 88

A 68-year-old man presents with progressive dyspnea and fatigue. Echocardiography reveals a reduced left ventricular ejection fraction and severe ischaemic ventricular secondary mitral regurgitation (SMR). Coronary angiography demonstrates complex multivessel coronary artery disease (CAD) requiring surgical revascularization. He is evaluated by the heart team and deemed a low-risk surgical candidate. Which of the following is the most appropriate management strategy?

• ✓ Mitral valve (MV) surgery at the time of coronary artery bypass grafting (CABG)
• ○ Transcatheter edge-to-edge repair (TEER) followed by isolated CABG
• ○ Isolated CABG with optimization of guideline-directed medical therapy for SMR
• ○ Percutaneous coronary intervention (PCI) followed by isolated MV surgery

Explanation. In patients with severe ischaemic ventricular secondary mitral regurgitation and concomitant coronary artery disease requiring coronary revascularization, mitral valve surgery at the time of coronary artery bypass grafting is the recommended approach when the patient is not at high surgical risk and the coronary anatomy requires surgical rather than percutaneous intervention.

Question 89

A 65-year-old man with a history of an anterior myocardial infarction presents with worsening exertional dyspnea. Echocardiography reveals a left ventricular ejection fraction of 30%, severe left ventricular dilatation, and severe secondary mitral regurgitation (SMR). Detailed structural analysis shows a pronounced mitral valve leaflet tenting area of 1.5 cm^2/m^2 body surface area (BSA). He is scheduled for surgical intervention. Which of the following is the most appropriate surgical approach for addressing the mitral valve in this patient?

• ✓ Mitral valve replacement
• ○ Mitral valve repair with restrictive annuloplasty
• ○ Coronary artery bypass grafting without mitral valve surgery
• ○ Mitral valve repair with isolated subvalvular modification

Explanation. In patients with severe secondary mitral regurgitation and pronounced left ventricular remodeling, specifically an increased mitral valve leaflet tenting area greater than 1.35 cm^2/m^2 body surface area, mitral valve replacement is typically required because mitral valve repair is associated with limited reverse ventricular remodeling and high rates of recurrent regurgitation.

Question 90

A 68-year-old male with heart failure (HF) and severe ventricular secondary mitral regurgitation (SMR) recently underwent a successful transcatheter edge-to-edge valve repair. At his 1-month post-procedure follow-up, he reports significant improvement in his dyspnea and exercise tolerance. He inquires about his future follow-up schedule and asks if he can stop taking his heart failure medications now that his valve has been repaired. What is the most appropriate management and counseling strategy for this patient?

• ✓ Schedule clinical, laboratory, and echocardiographic evaluations every 3 to 6 months and educate him on the importance of continuing his medical therapy.
• ○ Schedule clinical and echocardiographic evaluations annually and begin safely tapering his guideline-directed medical therapy.
• ○ Transfer his care to a general practitioner for annual follow-up, as the successful device intervention effectively resolves the underlying pathology.
• ○ Schedule clinical follow-up twice per year, and discontinue his medical therapies as the device and drugs serve the same physiological purpose.

Explanation. Patients who undergo intervention for ventricular secondary mitral regurgitation remain at an increased risk of long-term events, such as heart failure hospitalization or death. They require careful follow-up by a heart failure specialist, incorporating clinical, laboratory, and echocardiographic evaluations every 3 to 6 months depending on their heart failure stage. Device intervention and medical drugs are complementary treatments, and patients must be educated on the critical importance of not discontinuing their medical therapies post-intervention to optimize outcomes and prevent decompensation.

Question 91

A 72-year-old woman with a history of heart failure with preserved ejection fraction (HFpEF) and persistent atrial fibrillation (AF) presents with worsening exertional dyspnea. Echocardiography demonstrates a structurally normal mitral valve with moderate-to-severe secondary mitral regurgitation (SMR), severe left atrial (LA) dilatation, and a left ventricular ejection fraction of 62%. Her ventricular rate is well controlled at 78 beats per minute. In addition to optimizing her HFpEF medical regimen with a sodium-glucose cotransporter 2 inhibitor, which of the following management strategies may specifically contribute to reducing her SMR severity and reversing LA dilatation?

• ✓ Pursuing a rhythm-control strategy for her atrial fibrillation
• ○ Adding a mineralocorticoid receptor antagonist to her regimen
• ○ Proceeding directly to mitral transcatheter edge-to-edge repair
• ○ Initiating aggressive rate control to lower her resting heart rate below 60 beats per minute

Explanation. In patients with atrial secondary mitral regurgitation, utilizing a rhythm-control strategy for associated atrial fibrillation has been shown to potentially reduce the severity of the mitral regurgitation and reverse left atrial dilatation.

Question 92

A 78-year-old woman with long-standing persistent atrial fibrillation and heart failure presents with progressive dyspnea (NYHA class III) despite guideline-directed medical therapy. Transesophageal echocardiography reveals normal left ventricular dimensions and ejection fraction (58%), severe left atrial enlargement, and severe secondary mitral regurgitation (SMR). The mechanism of her SMR is isolated mitral annular dilation. The leaflets exhibit planar coaptation, a large central regurgitant jet, and a limited mitral valve area of 3.0 cm2. The Heart Team is discussing transcatheter edge-to-edge repair (TEER) versus surgical annuloplasty. Which of the following best describes a major concern regarding the use of TEER in this specific patient?

• ✓ The presence of planar leaflet coaptation and limited mitral valve area increases the risk of creating a significant transmitral gradient.
• ○ TEER is contraindicated in patients with atrial SMR because it accelerates left ventricular systolic dysfunction.
• ○ The large central regurgitant jet will cause severe left ventricular outflow tract obstruction after clip placement.
• ○ TEER is unable to reduce heart failure hospitalizations in patients with atrial SMR who have concurrent atrial fibrillation.

Explanation. When considering transcatheter edge-to-edge repair in patients with atrial secondary mitral regurgitation, anatomical factors such as planar leaflet coaptation, a large regurgitant jet, and a limited mitral valve area must be carefully evaluated due to the risk of creating an increased transmitral gradient.

Question 93

A 74-year-old female presents to the cardiology clinic for a routine follow-up. She has a history of heart failure with preserved ejection fraction (HFpEF) and persistent atrial fibrillation. Six months ago, she was diagnosed with severe atrial secondary mitral regurgitation (SMR) and subsequently underwent a transcatheter edge-to-edge repair (TEER). She is currently asymptomatic and doing well. What is the most appropriate long-term management and follow-up plan for this patient?

• ✓ Yearly clinical and echocardiographic evaluation, along with consultation with a heart failure specialist.
• ○ Clinical and echocardiographic evaluation every 6 months, with no further specialist consultation required.
• ○ Yearly clinical evaluation, with echocardiography reserved for recurrence of symptoms.
• ○ Yearly clinical and echocardiographic evaluation, along with consultation with an electrophysiologist for left atrial appendage occlusion.

Explanation. Patients with atrial secondary mitral regurgitation undergoing surgical or transcatheter intervention require follow-up on a yearly basis, which includes both clinical and echocardiographic evaluation. Furthermore, in cases where heart failure with preserved ejection fraction is the underlying cause of the atrial secondary mitral regurgitation, consultation with a heart failure specialist is necessary to optimize management.

Question 94

A 30-year-old female originally from a low-income nation presents with progressive exertional dyspnea and orthopnea. Physical examination reveals a loud S1 and a low-pitched mid-diastolic rumble at the cardiac apex. Transthoracic echocardiography confirms severe rheumatic mitral stenosis (MS). During the comprehensive echocardiographic assessment of the severity, anatomical lesions, and hemodynamic consequences of her condition, which of the following associated valvular findings must be specifically sought?

• ✓ Secondary tricuspid regurgitation (TR)
• ○ Primary pulmonary valve stenosis
• ○ Mitral annular calcification (MAC)
• ○ Carcinoid-related pulmonary valve retraction

Explanation. During the echocardiographic evaluation of a patient with mitral stenosis, it is essential to assess not only the primary mitral valve lesion but also the involvement of other valves. Specifically, secondary tricuspid regurgitation (TR) must be identified, as it frequently arises from the hemodynamic consequences of the left-sided valvular lesion.

Question 95

A 35-year-old woman with a history of rheumatic fever is evaluated for a heart murmur. A resting transthoracic echocardiogram (TTE) shows a thickened mitral valve with commissural fusion. The mitral valve area (MVA) is calculated at 1.3 cm² by 2D planimetry. Despite these imaging findings, the patient reports being completely asymptomatic and states she exercises daily without difficulty. Which of the following is the most appropriate next step in evaluating this patient's condition?

• ✓ Exercise echocardiography
• ○ Dobutamine stress echocardiography (DSE)
• ○ Systematic transesophageal echocardiography (TEE)
• ○ Referral for percutaneous mitral commissurotomy (PMC)

Explanation. Exercise echocardiography is indicated in asymptomatic patients who have severe mitral stenosis parameters (such as an MVA of 1.5 cm² or less) that are discordant with their reported lack of symptoms, as it provides objective information on true exercise capacity and exercise-induced changes in the mitral gradient and pulmonary artery pressure.

Question 96

A 38-year-old woman presents with significant exertional dyspnea (New York Heart Association Class III). She has a remote history of rheumatic fever. Transthoracic echocardiography demonstrates rheumatic mitral valve changes with an estimated mitral valve area (MVA) of 1.6 cm2. Her left ventricular ejection fraction is 65%. Extensive pulmonary and ischemic evaluations are unremarkable, and her symptoms are directly attributed to her mitral valve disease. Echocardiography also reveals a favorable mitral valve anatomy for percutaneous intervention without significant mitral regurgitation. Which of the following is the most appropriate statement regarding percutaneous mitral commissurotomy (PMC) for this patient?

• ✓ PMC may be considered given her unexplained symptoms and favorable valve anatomy.
• ○ PMC is strictly contraindicated because the patient's MVA is greater than 1.5 cm2.
• ○ She must undergo surgical mitral valve replacement as PMC is exclusively reserved for an MVA less than 1.0 cm2.
• ○ PMC is indicated only if she subsequently develops permanent atrial fibrillation or a left atrial thrombus.

Explanation. Percutaneous mitral commissurotomy may be considered in symptomatic patients with a mitral valve area of >1.5 cm2 if their symptoms cannot be explained by another cause and the valve anatomy is favorable for the procedure.

Question 97

A 42-year-old woman is evaluated for progressive exertional dyspnea and lower extremity edema. Transthoracic echocardiography (TTE) demonstrates severe rheumatic mitral stenosis with a mitral valve area of 1.1 cm² and concomitant severe secondary tricuspid regurgitation (TR) due to post-capillary pulmonary hypertension. An electrocardiogram shows normal sinus rhythm. Left atrial size is moderately enlarged. The heart team evaluates her and determines her overall surgical risk is low. What is the most appropriate management strategy for this patient?

• ○ Percutaneous mitral commissurotomy (PMC) alone
• ✓ Surgical intervention on both the mitral and tricuspid valves
• ○ Percutaneous mitral commissurotomy (PMC) followed by transcatheter tricuspid valve repair
• ○ Isolated surgical mitral valve replacement

Explanation. In patients presenting with severe mitral stenosis and concomitant severe tricuspid regurgitation who are not at high surgical risk, surgical intervention on both valves is the preferred management strategy.

Question 98

An 83-year-old male with a history of peripheral arterial disease and hypertension is found to have extensive mitral annular calcification on a transthoracic echocardiogram. He currently has no symptoms of heart failure or dyspnea on exertion. Which of the following is the most accurate statement regarding the pathophysiology and clinical implications of his echocardiographic findings?

• ✓ Mitral annular calcification is an indicator of cardiovascular disease severity that increases the risk for atrial fibrillation and stroke, though most affected patients do not have significant valvular dysfunction; when mitral stenosis occurs, it is generally due to calcific extension into the leaflets or subvalvular apparatus.
• ○ Mitral annular calcification is an isolated, benign finding of aging; however, if mitral stenosis develops, it is typically mediated by concurrent rheumatic commissural fusion rather than direct calcific extension.
• ○ The patient most likely has significant, undiagnosed mitral regurgitation, as the vast majority of patients with extensive mitral annular calcification present with severe valvular dysfunction requiring prompt surgical intervention.
• ○ If the patient eventually develops combined mitral stenosis and regurgitation, robust evidence from randomized controlled trials dictates that transcatheter approaches are the preferred, low-risk treatment of choice.

Explanation. Mitral annular calcification is a marker of overall cardiovascular disease severity and carries an increased risk of subsequent clinical events, including atrial fibrillation, stroke, and death. Despite these associated risks, the majority of patients with mitral annular calcification do not actually exhibit significant valvular dysfunction at baseline. In cases where mitral stenosis does eventually develop, the underlying pathophysiological mechanism is typically the direct extension of the calcific process into the mitral valve leaflets or the subvalvular apparatus.

Question 99

A 78-year-old woman with a history of hypertension presents with NYHA class III heart failure symptoms. Transthoracic echocardiography reveals severe mitral annular calcification (MAC) resulting in severe degenerative mitral stenosis and a high mean transmitral gradient. Given her persistent symptoms despite maximal medical therapy, the heart team is evaluating her for a potential surgical or transcatheter mitral valve intervention. Which of the following imaging modalities is necessary to specifically assess the degree and anatomic locations of the annular calcifications prior to the planned procedure?

• ✓ Electrocardiogram-gated cardiac computed tomography (CCT)
• ○ Three-dimensional transesophageal echocardiography (3D-TOE)
• ○ Cardiac magnetic resonance (CMR) imaging
• ○ Fluoroscopy

Explanation. Electrocardiogram-gated cardiac computed tomography (CCT) is necessary to accurately assess the degree and specific locations of calcifications in patients with degenerative mitral stenosis, particularly when an intervention is planned.

Question 100

An 82-year-old female presents with New York Heart Association (NYHA) class III dyspnea. Echocardiography reveals clinically severe mitral stenosis (MS) secondary to extensive degenerative mitral annular calcification (MAC). She is evaluated by the Heart Team and deemed to be at high risk for conventional open mitral valve surgery. Which of the following statements regarding transcatheter or surgical interventions for this patient's specific valvular pathology is correct?

• ○ Percutaneous mitral commissurotomy (PMC) is the initial procedure of choice due to high success rates in calcific degenerative disease.
• ○ Transcatheter implantation of a transcatheter aortic valve implantation (TAVI) prosthesis in the mitral position is preferred because it eliminates the risk of left ventricular outflow tract (LVOT) obstruction.
• ✓ The use of dedicated transcatheter mitral valve implantation (TMVI) devices is encouraged as it appears to be safer than utilizing a TAVI prosthesis.
• ○ The Heart Team should routinely pursue intervention because successful transcatheter treatment typically reduces 1-year mortality to less than 2%.

Explanation. In the management of severe degenerative mitral stenosis, the use of dedicated transcatheter mitral valve implantation (TMVI) devices is encouraged because it appears to be safer than utilizing a transcatheter aortic valve implantation (TAVI) prosthesis in the mitral position, which is associated with frequent complications including left ventricular outflow tract (LVOT) obstruction, valve embolization, stroke, and hemolysis due to paravalvular leak.

Question 101

A 68-year-old female with a history of rheumatic heart disease presents with progressively worsening dyspnea on exertion. Transoesophageal echocardiography (TOE) demonstrates severe mitral stenosis with a mitral valve area of 1.1 cm², an echocardiographic score of 6, and no significant mitral regurgitation. During the imaging, a small thrombus is visualized localized in the left atrial appendage. She has severe severe chronic obstructive pulmonary disease and frailty, making her an extremely poor candidate for surgical intervention. Her current clinical condition is stable, without an urgent need for immediate mechanical relief of the stenosis. What is the most appropriate approach to facilitate a percutaneous mitral commissurotomy (PMC) in this patient?

• ✓ Initiate oral anticoagulation for 1 to 3 months and proceed with PMC provided a repeat TOE confirms resolution of the thrombus.
• ○ Proceed with immediate PMC because the thrombus is isolated to the appendage and her echocardiographic score is favorable.
• ○ Refer the patient for surgical mitral valve replacement despite the surgical risk, as any left atrial appendage thrombus is an absolute contraindication to PMC.
• ○ Schedule a PMC with simultaneous surgical left atrial appendage ligation to prevent systemic embolization during the procedure.

Explanation. In a patient with a left atrial appendage thrombus who has contraindications to surgery or lacks an urgent need for intervention, oral anticoagulation can be safely administered for 1 to 3 months. Percutaneous mitral commissurotomy can then be considered and performed, provided that a repeat transoesophageal echocardiography confirms the complete resolution of the thrombus.

Question 102

A 78-year-old woman is evaluated for exertional dyspnea and peripheral edema. Transthoracic echocardiography demonstrates severe tricuspid regurgitation (TR). Right and left ventricular systolic functions are preserved, and the estimated pulmonary artery systolic pressure is normal. Which of the following statements is true regarding the prognostic implications and etiology of her echocardiographic findings?

• ✓ Her severe TR is associated with an increased risk of mortality and heart failure, independent of her preserved ventricular function and normal pulmonary pressures.
• ○ Because her ventricular function and pulmonary pressures are normal, her severe TR is considered a benign condition that does not impact long-term mortality.
• ○ It is highly likely that her TR is caused by a primary anatomical abnormality of the tricuspid valve apparatus, such as myxomatous disease or carcinoid syndrome.
• ○ Severe TR in this age group is extremely rare, with a prevalence of less than 0.5% in patients over the age of 75 years.

Explanation. Severe tricuspid regurgitation is associated with an increased risk of death and heart failure, and this prognostic risk remains independent of the patient's baseline comorbidities, ventricular function, and pulmonary pressures.

Question 103

A 72-year-old man with a long-standing history of persistent atrial fibrillation presents with progressive lower extremity edema and exertional fatigue. Echocardiography reveals severe secondary tricuspid regurgitation with structurally normal leaflets. He is suspected to have early-stage atrial secondary tricuspid regurgitation. Which of the following echocardiographic feature profiles is most characteristic of this specific condition?

• ✓ Marked right atrial and annular dilatation, absence of significant leaflet tethering, and preserved right ventricular size and pulmonary pressures.
• ○ Significant leaflet tethering, tricuspid annular dilatation, and right ventricular dilation due to chronic pre-capillary pulmonary hypertension.
• ○ Marked right atrial dilation, severe tricuspid leaflet tethering, and severely depressed left ventricular ejection fraction.
• ○ Structurally abnormal tricuspid leaflets with severe flail segments, right atrial dilatation, and preserved right ventricular function.

Explanation. Atrial secondary tricuspid regurgitation is primarily associated with atrial fibrillation and is characterized morphologically by marked right atrial and tricuspid annular dilatation without significant leaflet tethering, along with preserved right ventricular size and function, preserved pulmonary pressures, and preserved left ventricular function.

Question 104

A 74-year-old female presents for evaluation of right-sided heart failure. She has been treated with diuretics and is currently in a euvolaemic state with optimized systemic and pulmonary pressures. A transthoracic echocardiogram incorporating 3D and strain analysis demonstrates a central tricuspid regurgitation (TR) jet. Using an integrative multi-parametric approach, the TR is definitively graded as "severe", though it does not meet the criteria for "massive" or "torrential" on the extended five-grade scale. Which of the following is the most appropriate approach regarding structural intervention for her TR?

• ✓ Consider intervention without delay with the aim of reducing the tricuspid regurgitation to moderate or less.
• ○ Defer intervention and monitor with serial echocardiography until the tricuspid regurgitation progresses to the "massive" grade.
• ○ Discontinue diuretic therapy to reassess the tricuspid regurgitation severity in a hypervolaemic state prior to planning intervention.
• ○ Perform transoesophageal echocardiography to definitively upgrade the tricuspid regurgitation to "torrential" before considering intervention.

Explanation. Intervention should be considered without delay as soon as tricuspid regurgitation is graded as severe, with the procedural aim of reducing the regurgitation to moderate or less. While an extended five-grade scale including 'massive' and 'torrential' grades can help refine the assessment of regurgitation reduction after transcatheter interventions and correlates with event risk, clinical intervention should not be delayed once the threshold of 'severe' has been met in an appropriately evaluated, euvolaemic patient.

Question 105

A 74-year-old woman with worsening peripheral edema and exertional fatigue is being evaluated for a percutaneous tricuspid valve intervention. Transthoracic echocardiography demonstrates severe tricuspid regurgitation (TR) and a dilated right ventricle (RV) with an estimated fractional area change of 42%. The estimated systolic pulmonary artery pressure derived from the tricuspid regurgitant jet is 30 mmHg. What is the most appropriate next step in the diagnostic evaluation prior to proceeding with the intervention?

• ✓ Perform right heart catheterization to evaluate for masked severe pre-capillary pulmonary hypertension.
• ○ Proceed directly to the intervention as echocardiography reliably confirms normal pulmonary artery pressures.
• ○ Utilize lower thresholds to define RV dysfunction since echocardiography typically underestimates right ventricular systolic function in severe TR.
• ○ Avoid cardiac magnetic resonance imaging as it is less accurate than echocardiography for assessing right ventricular volumes.

Explanation. Right heart catheterization is essential in all candidates for an intervention because echocardiography often underestimates pulmonary pressures in the setting of severe tricuspid regurgitation. Invasive assessment is necessary to accurately measure pulmonary pressures and vascular resistance, evaluate the hemodynamic consequences on the venous circulation, and definitively exclude masked severe pre-capillary pulmonary hypertension prior to an intervention.

Question 106

A 72-year-old male presents with severe tricuspid regurgitation (TR) and signs of progressive right-sided heart failure. Echocardiography is performed to evaluate right ventricular (RV) function and pulmonary hemodynamics. The ratio of tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary artery pressure (SPAP) is calculated to be 0.18 mm/mmHg (normal > 0.36 mm/mmHg). Which of the following best describes the pathophysiological state and prognostic implication of this echocardiographic finding?

• ✓ It indicates RV-pulmonary artery uncoupling, where RV contractile reserve cannot match sustained increases in afterload, and is associated with a poor prognosis.
• ○ It indicates RV-pulmonary artery coupling, where RV systolic performance adequately matches pulmonary afterload, ensuring a favorable prognosis.
• ○ It indicates right ventricular adaptation to isolated pulmonary hypertension, predicting a high likelihood of functional recovery.
• ○ It represents a compensatory reduction in RV systolic function to limit right-sided cardiac output, protecting the pulmonary vascular bed.

Explanation. A low ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure (TAPSE/SPAP) represents RV-pulmonary artery uncoupling. This pathophysiological state occurs when sustained increases in pulmonary afterload cannot be matched by right ventricular contractile reserve to maintain adequate cardiac output, and it is associated with a poor prognosis in various heart failure conditions, including severe tricuspid regurgitation.

Question 107

A 70-year-old female presents with progressive fatigue, abdominal fullness, and lower extremity edema. Echocardiography confirms severe tricuspid regurgitation (TR) with moderate right ventricular (RV) dysfunction. Laboratory results show mild hepatic impairment. The Heart Team evaluates the patient and calculates a TRI-SCORE of 5. If considering isolated tricuspid valve (TV) surgery to improve long-term (10-year) survival, which of the following statements is most accurate regarding the expected benefit for this patient?

• ✓ Improved 10-year survival is observed only after successful TV repair.
• ○ Improved 10-year survival is observed after both TV repair and TV replacement.
• ○ Any TV intervention provides no survival benefit compared with conservative management for this score.
• ○ Improved 10-year survival is observed only after isolated TV replacement.

Explanation. In patients with an intermediate TRI-SCORE of 4 to 5, isolated tricuspid valve surgery is associated with improved survival at 10 years specifically after successful valve repair, distinguishing this group from those with a low score (≤3) who derive 10-year survival benefit from either repair or replacement.

Question 108

A 68-year-old male with a history of complete heart block treated with a dual-chamber permanent pacemaker 5 years ago presents with progressive fatigue, abdominal fullness, and lower extremity edema. Echocardiography demonstrates severe tricuspid regurgitation, and the right ventricular pacemaker lead is found to be entrapping the septal tricuspid leaflet. He is optimized on loop diuretics and an aldosterone antagonist, but his right-sided heart failure symptoms persist. The patient is referred for surgical intervention. Which of the following approaches is most appropriate to manage the pacing system and optimize tricuspid valve function?

• ✓ Lead extraction with implantation of an epicardial system and preparation of the entrapped leaflet
• ○ Implantation of an additional right ventricular lead to provide alternative pacing while leaving the entrapped lead in place
• ○ Tricuspid valve repair using a rigid annuloplasty ring deployed directly over the entrapped pacemaker lead
• ○ Abandonment of the entrapped lead and placement of a leadless pacemaker in the right ventricle

Explanation. In cases of cardiovascular implantable electronic device-related tricuspid regurgitation, preparation of any entrapped tricuspid leaflet combined with lead extraction and the implantation of an epicardial pacing system is associated with improved tricuspid valve function.

Question 109

A 68-year-old woman presents with worsening peripheral edema and fatigue. Transthoracic echocardiogram reveals a flail tricuspid leaflet, a proximal isovelocity surface area (PISA) radius of 11 mm (at a Nyquist limit of 28 cm/s), and a dense, triangular continuous-wave Doppler jet with early peaking, consistent with severe primary tricuspid regurgitation (TR). Her right ventricular (RV) and left ventricular (LV) systolic functions are preserved, and invasive hemodynamics show a mean pulmonary arterial pressure of 16 mmHg. She is symptomatic but has no indication for left-sided valve surgery. Which of the following is the most appropriate management for this patient?

• ✓ Surgical intervention
• ○ Medical management with close echocardiographic surveillance until RV function deteriorates
• ○ Percutaneous balloon valvuloplasty
• ○ Heart-lung transplantation

Explanation. Surgical intervention is recommended as the definitive treatment in operable symptomatic patients with severe primary tricuspid regurgitation who do not require left-sided valve surgery, provided they do not have prohibitive surgical risks such as severe LV/RV dysfunction or severe pulmonary hypertension.

Question 110

A 68-year-old woman presents with worsening exertional dyspnea, fatigue, and bilateral lower extremity edema. Transthoracic echocardiography demonstrates severe rheumatic mitral stenosis with a mitral valve area of 0.9 cm², a dilated right atrium, and severe secondary tricuspid regurgitation (TR). She is evaluated by the heart team and is scheduled to undergo surgical mitral valve replacement. Which of the following is the most appropriate management strategy regarding her tricuspid valve?

• ○ Perform isolated mitral valve replacement, as the secondary TR is highly likely to resolve once left-sided hemodynamics are corrected.
• ✓ Perform concurrent tricuspid valve surgery at the time of the mitral valve replacement.
• ○ Defer tricuspid valve surgery and manage the TR medically, scheduling a reoperation only if right-sided heart failure becomes refractory.
• ○ Perform isolated mitral valve replacement and plan for an elective transcatheter tricuspid valve intervention six months later.

Explanation. Severe primary or secondary tricuspid regurgitation is unlikely to improve after isolated surgical treatment of left-sided valve disease, and future reoperation for tricuspid regurgitation treatment is associated with high peri-operative mortality. Therefore, performing tricuspid valve surgery concurrently at the time of the index left-sided procedure is the appropriate management strategy.

Question 111

A 65-year-old woman is scheduled to undergo surgical mitral valve replacement for severe rheumatic mitral stenosis. Preoperative echocardiography reveals moderate tricuspid regurgitation. The heart team recommends a concomitant tricuspid valve repair annuloplasty. The patient asks about the potential benefits and risks of adding the tricuspid procedure to her mitral valve surgery. Which of the following is a recognized outcome of performing concomitant tricuspid valve repair in this scenario?

• ○ Reduction in overall long-term mortality
• ✓ Higher risk of conduction disturbances requiring pacemaker implantation
• ○ Decreased incidence of postoperative heart failure hospitalizations
• ○ Reduced need for late reoperation due to recurrent tricuspid valve disease

Explanation. Concomitant tricuspid valve repair during mitral valve surgery in patients with moderate tricuspid regurgitation is associated with an increased risk of conduction disturbances that necessitate permanent pacemaker implantation, with rates reported up to 14%.

Question 112

A 72-year-old man is scheduled to undergo left-sided valve surgery for severe mitral regurgitation. Preoperative echocardiography reveals mild-to-moderate secondary tricuspid regurgitation (TR), significant right atrial dilation, and elevated pulmonary pressures. He also has a history of atrial fibrillation. The surgical team is debating whether to perform a concomitant tricuspid annuloplasty to prevent progressive TR. What major postoperative risk must be carefully balanced against the potential benefits of adding the tricuspid annuloplasty?

• ✓ The risk of postoperative pacemaker implantation, which is associated with subsequent increases in heart failure hospitalizations, endocarditis, and mortality.
• ○ The risk of creating severe pre-capillary pulmonary hypertension due to a restrictive tricuspid annulus.
• ○ The risk of precipitating severe right ventricular dysfunction by suddenly increasing right-sided afterload.
• ○ The risk of structural valve deterioration requiring subsequent transcatheter edge-to-edge repair.

Explanation. When considering tricuspid annuloplasty in patients with risk factors for progressive annular dilatation and tricuspid regurgitation (e.g., atrial fibrillation, right atrial size, elevated pulmonary pressures), the potential benefits must be balanced against the risk of possible pacemaker implantation. The need for a pacemaker after surgery leads to a subsequent increase in heart failure hospitalizations, endocarditis, and mortality.

Question 113

A 76-year-old male with severe, symptomatic tricuspid regurgitation is evaluated for transcatheter edge-to-edge repair (TEER). He is currently optimized on medical therapy but continues to experience significant fatigue and peripheral edema. Anatomical suitability for tricuspid TEER is confirmed by echocardiography. When discussing the expected outcomes of the procedure compared to medical therapy alone based on the TRILUMINATE Pivotal Trial, which of the following was shown to exclusively drive the improvement in the primary composite endpoint?

• ○ A significant reduction in all-cause mortality
• ○ A significant reduction in the need for future tricuspid valve surgery
• ○ A significant reduction in heart failure hospitalizations at 30 days
• ✓ A significant improvement in quality of life

Explanation. In the TRILUMINATE Pivotal Trial, the improvement in the composite endpoint (death from any cause or tricuspid valve surgery, heart failure hospitalization, and improvement in quality of life) after tricuspid TEER compared with medical treatment was exclusively driven by an improved quality of life as measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

Question 114

An 81-year-old male is evaluated in the structural heart disease clinic for refractory symptoms of right heart failure, including severe peripheral edema and exertional fatigue, despite maximized guideline-directed medical therapy. Echocardiography demonstrates severe tricuspid regurgitation (TR). The Heart Team deems him to be at high surgical risk and considers a transcatheter tricuspid valve intervention. Which of the following findings would preclude this patient from being an appropriate candidate for transcatheter tricuspid valve treatment?

• ✓ Pre-capillary pulmonary hypertension
• ○ Post-capillary pulmonary hypertension
• ○ Mild right ventricular systolic dysfunction
• ○ The presence of a transvenous cardiovascular implantable electronic device

Explanation. Transcatheter treatment for tricuspid regurgitation should be considered to improve quality of life and promote right ventricular remodeling in high-risk patients with symptomatic severe tricuspid regurgitation who remain symptomatic despite optimal medical therapy. However, candidates must be carefully selected, and transcatheter interventions are not indicated in patients with severe right ventricular dysfunction or pre-capillary pulmonary hypertension.

Question 115

A 76-year-old male with a history of severe mitral regurgitation and tricuspid regurgitation (TR) underwent mitral valve replacement and tricuspid annuloplasty 8 years ago. He now presents with worsening peripheral edema, fatigue, and right upper quadrant abdominal pain. Echocardiography reveals severe recurrent TR. After evaluation by the Heart Team, he is deemed at prohibitive surgical risk for a cardiac reoperation, and a transcatheter valve-in-ring implantation is being considered as an off-label option. Which of the following represents a significant anatomical challenge specific to this procedure?

• ○ The proximity of the tricuspid annulus to the atrioventricular node.
• ✓ The non-circular shape and the open form of the surgical annuloplasty ring.
• ○ The high risk of left ventricular outflow tract obstruction.
• ○ The rigid and extensively calcified nature of the native tricuspid annulus.

Explanation. Transcatheter valve-in-ring implantation is utilized as a treatment for residual or recurrent tricuspid regurgitation in high-risk patients; however, the procedure faces significant anatomical challenges specifically due to the non-circular shape and the open form of the surgical annuloplasty ring that was previously implanted.

Question 116

A 52-year-old woman with a history of rheumatic fever in childhood presents with progressive fatigue, abdominal fullness, and bilateral lower extremity edema. On physical examination, jugular venous distension with a prominent 'a' wave is noted, along with hepatomegaly. A diastolic murmur is heard along the left lower sternal border, which increases in intensity with inspiration. Transthoracic echocardiography reveals significant thickening and commissural fusion of the tricuspid valve leaflets. Which of the following Doppler echocardiographic findings at a normal heart rate confirms the diagnosis of severe tricuspid stenosis?

• ✓ A mean diastolic transvalvular gradient > 5 mmHg
• ○ A mean systolic transvalvular gradient > 10 mmHg
• ○ A peak diastolic transvalvular gradient > 5 mmHg
• ○ A mean diastolic transvalvular gradient > 2 mmHg

Explanation. A mean diastolic transvalvular gradient of >5 mmHg at a normal heart rate indicates severe tricuspid stenosis.

Question 117

A 48-year-old female with a history of rheumatic heart disease presents with progressive fatigue, abdominal fullness, and lower extremity edema. Echocardiography demonstrates severe tricuspid stenosis with heavily calcified leaflets, requiring valve replacement. The heart team recommends a biological heart valve over a mechanical heart valve for the tricuspid position. Which of the following provides the primary rationale for this recommendation?

• ✓ Mechanical heart valves carry a high risk of thrombogenicity in the low-pressure system.
• ○ Mechanical heart valves undergo rapid structural degeneration in the right side of the heart.
• ○ Biological heart valves allow for future balloon valvuloplasty when structural degeneration occurs.
• ○ Rheumatic etiology significantly increases the risk of mechanical leaflet calcification and subsequent failure.

Explanation. Biological heart valves are preferred over mechanical heart valves in the tricuspid position due to the high thrombogenicity associated with mechanical valves in the low-pressure system of the right heart.

Question 118

A 72-year-old woman with a history of rheumatic fever presents with progressive dyspnoea. Transthoracic echocardiography reveals both severe mitral regurgitation and moderate aortic stenosis. The cardiologist attempts to quantify the severity of the aortic stenosis using the continuity equation. Which of the following best describes a major limitation of using this method in this patient?

• ✓ The continuity equation may yield erroneous results because the transvalvular flows are unequal.
• ○ The continuity equation is primarily limited by the altered left ventricular compliance frequently seen in mixed valve disease.
• ○ The continuity equation is inaccurate due to the hyperdynamic high-flow states commonly associated with multiple valve defects.
• ○ The continuity equation relies on pressure half-time measurements, which are invalidated by the presence of mitral regurgitation.

Explanation. In patients with multiple and mixed valve lesions, haemodynamic interdependence alters loading and flow conditions. Consequently, the continuity equation becomes erroneous when transvalvular flows are unequal due to the combined presence of different valvular defects.

Question 119

A 72-year-old male with a history of rheumatic heart disease presents with progressive fatigue and peripheral edema. Echocardiography reveals a reduced left ventricular ejection fraction of 35%, low-flow, low-gradient aortic stenosis, and severe tricuspid regurgitation. The care team considers various diagnostic modalities to further characterize his multiple valvular heart disease (MVHD) and determine the appropriate management strategy. Which of the following diagnostic approaches is most likely to yield inaccurate results in this patient?

• ✓ Cardiac output measurement using thermodilution
• ○ Valvular regurgitation assessment using direct flow quantification by cardiac magnetic resonance imaging
• ○ Evaluation of functional capacity using cardiopulmonary exercise testing
• ○ Confirmation of aortic stenosis severity using aortic valve calcium scoring

Explanation. Invasive cardiac output-derived measures based on thermodilution or the Fick equation using estimated oxygen uptake are inaccurate in low-flow conditions or in the presence of severe tricuspid regurgitation, both of which are commonly present in multiple valvular heart disease.

Question 120

A 42-year-old female who recently immigrated from a low-income nation presents to the cardiology clinic with progressive exertional dyspnea and lower extremity edema. Auscultation reveals a loud S1, an opening snap, a diastolic rumble at the apex, and a blowing diastolic murmur at the right upper sternal border. Transthoracic echocardiography confirms the presence of moderate mitral stenosis with severe mitral regurgitation (mixed valvular heart disease) and moderate aortic regurgitation (multiple valvular heart disease). Given the patient's demographic background, what is the most likely primary etiology of her complex valvular presentation?

• ○ Degenerative valvular disease
• ✓ Rheumatic heart disease
• ○ Radiation-induced valvulopathy
• ○ Atrioventricular valve regurgitation secondary to cardiomyopathy

Explanation. Rheumatic heart disease remains the leading etiology of multiple valvular heart disease and mixed valvular heart disease in patients from low- and middle-income countries.

Question 121

A 68-year-old woman is referred for surgical intervention due to severe primary mitral regurgitation causing symptomatic heart failure. Preoperative echocardiography also identifies concomitant moderate aortic stenosis (AS) with a heavily calcified trileaflet aortic valve. When planning her surgical procedure, what is the most appropriate approach to her aortic valve disease?

• ✓ Simultaneous surgical treatment of the moderate AS should be considered.
• ○ Surgical intervention for the aortic valve should be deferred until the stenosis becomes severe.
• ○ A staged approach with subsequent transcatheter aortic valve implantation is the preferred strategy.
• ○ Medical management of the aortic valve is recommended due to the increased operative risk of double-valve surgery.

Explanation. In patients with multiple primary valvular heart disease who require surgical treatment for a severe valvular lesion, simultaneous treatment of concomitant moderate aortic stenosis should be considered to address all relevant primary valvular defects.

Question 122

An 83-year-old man with a history of heart failure is evaluated for worsening dyspnea. Echocardiography reveals severe aortic stenosis, severe primary mitral regurgitation, and severe primary tricuspid regurgitation. The Heart Team determines that the patient is at high surgical risk, but his anatomy is suitable for transcatheter interventions. Which of the following is the preferred transcatheter treatment strategy for this patient?

• ○ A staged approach beginning with the tricuspid valve, followed by the mitral valve, and lastly the aortic valve.
• ✓ A staged approach beginning with the aortic valve, followed by the mitral valve, and lastly the tricuspid valve.
• ○ Simultaneous transcatheter intervention for all three valves during a single procedure to minimize anesthesia time.
• ○ A staged approach beginning with the mitral valve, followed by the aortic valve, and lastly the tricuspid valve.

Explanation. In the context of a transcatheter strategy for multiple valvular heart disease, a staged approach is generally preferred to avoid potential haemodynamic deterioration. This staged approach typically begins with the most downstream lesion, which is the aortic valve, followed sequentially by the mitral and then the tricuspid valves.

Question 123

A 72-year-old male presents to the cardiology clinic with progressive exertional dyspnea and occasional episodes of lightheadedness. Transthoracic echocardiography reveals mixed aortic valve (AV) disease characterized by balanced moderate aortic stenosis (AS) and moderate aortic regurgitation (AR). His left ventricular ejection fraction is 52%. Based on the hemodynamic impact of combined moderate stenotic and regurgitant lesions, which of the following best describes this patient's prognostic risk profile?

• ✓ His risk of adverse events is comparable to that of a patient with severe isolated aortic stenosis.
• ○ His risk of adverse events is comparable to isolated moderate aortic regurgitation, reflecting a benign short-term prognosis.
• ○ The combined moderate lesions counteract each other's ventricular loading conditions, leading to a lower risk of adverse events.
• ○ His risk of adverse events is primarily driven by the regurgitant volume and is comparable to severe isolated aortic regurgitation.

Explanation. The severity of mixed aortic valve disease is frequently underestimated in clinical practice, as patients presenting with balanced moderate aortic regurgitation and moderate aortic stenosis exhibit adverse event rates that are comparable to those seen in patients with severe isolated aortic stenosis.

Question 124

A 72-year-old man presents with progressive exertional dyspnea and fatigue over the past six months. Transthoracic echocardiography reveals mixed aortic valve disease characterized by moderate aortic regurgitation and a calculated aortic valve area of 1.3 cm². Doppler evaluation demonstrates a high transvalvular mean gradient of 48 mmHg. Left ventricular ejection fraction is 58%. What is the most appropriate next step in management?

• ✓ Proceed with aortic valve intervention
• ○ Defer intervention and perform clinical and echocardiographic follow-up
• ○ Perform multimodality assessment with global longitudinal strain and natriuretic peptides
• ○ Refer for transesophageal echocardiography to precisely planimeter the aortic valve area

Explanation. Transvalvular gradients measured by Doppler reflect the overall hemodynamic burden of combined regurgitation and stenosis and are strongly associated with adverse outcomes. The presence of high transvalvular gradients justifies proceeding with valve intervention in patients with moderate mixed aortic valve disease, even when the regurgitation is graded as moderate and the calculated or planimetric aortic valve area is greater than 1 cm².

Question 125

A 64-year-old woman is diagnosed with mixed valvular heart disease (MVHD), specifically moderate aortic stenosis (aortic valve area 1.3 cm², mean gradient 32 mmHg) and moderate aortic regurgitation. She is currently asymptomatic with normal left ventricular ejection fraction. When determining the appropriate follow-up schedule for this patient, which of the following is an important consideration compared to a patient with isolated moderate single-valve disease?

• ✓ Progression of severity and development of cardiac damage may be faster due to the cumulative hemodynamic impact.
• ○ The antagonistic hemodynamic effects of stenosis and regurgitation result in slower progression.
• ○ Follow-up intervals should be standardized to every 3-5 years regardless of individual characteristics.
• ○ Mixed valvular disease only impacts right ventricular function and spares the left ventricle.

Explanation. Due to the cumulative hemodynamic impact of mixed valvular heart disease, progression of its severity and the development of cardiac damage may be faster than in single valvular heart disease, necessitating follow-up intervals that are adjusted according to individual patient characteristics.

Question 126

A 50-year-old man with severe symptomatic mitral stenosis and permanent atrial fibrillation is scheduled for mitral valve replacement. He is currently maintained on warfarin with a stably controlled International Normalized Ratio (INR). His medical history is otherwise unremarkable, and he has a low bleeding risk. What is the most appropriate choice of valve prosthesis for this patient, and what is the primary rationale?

• ✓ Mechanical heart valve, because it is preferred in younger patients with a longer life expectancy and those with a pre-existing indication for long-term oral anticoagulation.
• ○ Bioprosthetic heart valve, because the rheumatic etiology of his valve disease mandates the use of tissue over mechanical prostheses.
• ○ Bioprosthetic heart valve, because it is specifically indicated for patients who can easily maintain stable INRs with adequate times in the therapeutic range.
• ○ Mechanical heart valve, because it is generally preferred in patients with an increased bleeding risk due to frailty or comorbidities.

Explanation. A mechanical heart valve is the preferred choice in younger patients who have a longer life expectancy and in individuals who already possess a pre-existing indication for long-term oral anticoagulation, such as those with permanent atrial fibrillation.

Question 127

A 30-year-old male with severe symptomatic aortic stenosis is referred for surgical valve replacement. He is a professional athlete who wishes to avoid lifelong oral anticoagulation and is inquiring about alternatives to a mechanical heart valve. Which of the following is the most appropriate consideration regarding valve selection for this patient?

• ✓ Replacement of the aortic valve using an autograft (Ross procedure) is a viable alternative, provided it is performed at an experienced center by operators with dedicated expertise.
• ○ A biological heart valve is preferred, as observational studies demonstrate it offers lower long-term mortality than a mechanical heart valve in aortic valve patients under the age of 60.
• ○ A mechanical heart valve must be utilized because no other surgical alternatives exist for young patients requiring aortic valve replacement.
• ○ A biological heart valve is recommended because adequately powered randomized controlled trials have established its survival benefit in patients under the age of 50.

Explanation. Replacement of the aortic valve using an autograft, known as the Ross procedure, serves as an established surgical alternative to a mechanical heart valve in young patients and provides excellent outcomes when performed at experienced centers by operators with dedicated expertise in the technique.

Question 128

A 68-year-old male with a history of a bioprosthetic aortic valve replacement 3 years ago presents with 2 weeks of fevers, chills, and fatigue. Blood cultures are positive for Staphylococcus aureus. Transthoracic echocardiography (TTE) is performed but is limited by poor acoustic windows. A subsequent transoesophageal echocardiography (TOE) shows no definitive vegetations, but prosthetic valve endocarditis is still highly suspected. Which of the following is the most appropriate next step in the imaging evaluation of this patient?

• ✓ Perform cardiac computed tomography (CCT) and positron emission tomography-computed tomography (PET-CT).
• ○ Perform cinefluoroscopy to assess leaflet motion and morphology.
• ○ Repeat TTE in 3 months to monitor for disease progression.
• ○ Initiate empiric thrombolytic therapy to address potential valve dysfunction.

Explanation. In cases of suspected prosthetic valve endocarditis where the echocardiographic diagnosis remains unclear, cardiac computed tomography (CCT) and positron emission tomography-computed tomography (PET-CT) are recommended to clarify the diagnosis and to identify primary or secondary infection foci.

Question 129

A 52-year-old female undergoes mitral valve replacement with a mechanical heart valve. Her postoperative recovery is uncomplicated, and there is no evidence of active bleeding. The surgical team consults you regarding the initiation of anticoagulation therapy. Based on the most appropriate management strategy, which of the following is correct regarding the bridging and transition to long-term anticoagulation in this patient?

• ✓ Bridging with therapeutic unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) and a vitamin K antagonist (VKA) should be initiated within 24 hours, with heparin stopped once the INR is therapeutic for 2 consecutive days.
• ○ Bridging with therapeutic LMWH and a VKA should be delayed for at least 72 hours to allow for surgical site hemostasis, continuing LMWH until the INR is therapeutic for 2 consecutive days.
• ○ Bridging with therapeutic UFH and a VKA should be initiated within 24 hours, with UFH stopped as soon as the first INR reading is documented within the therapeutic range.
• ○ A direct oral anticoagulant (DOAC) should be initiated within 24 hours as a bridging agent to a VKA, stopping the DOAC once the INR is therapeutic for 2 consecutive days.

Explanation. Bridging with either therapeutic unfractionated heparin or low-molecular-weight heparin and a vitamin K antagonist should be initiated within 24 hours after mechanical heart valve implantation, or as soon as considered safe. The heparin bridging can be safely stopped when the INR is documented for 2 consecutive days within the therapeutic range.

Question 130

A 55-year-old male with a mechanical mitral valve is evaluated after suffering a recent ischemic stroke. His medical records show that he has been highly compliant with his warfarin therapy. Over the past year, his target international normalized ratio (INR) has been 3.0 (range 2.5-3.5), and his time in therapeutic range (TTR) is 75%. There is no evidence of infective endocarditis or atrial fibrillation. Which of the following is the most appropriate modification to his antithrombotic regimen to prevent further thromboembolic events?

• ○ Switch warfarin to a direct oral anticoagulant (e.g., apixaban).
• ○ Discontinue warfarin and initiate dual antiplatelet therapy (DAPT).
• ○ Maintain the current warfarin target and add prophylactic doses of a low-molecular-weight heparin.
• ✓ Increase the target INR to 3.5 (range 3.0-4.0).

Explanation. In patients with a mechanical heart valve who develop a major thromboembolic complication despite an adequate INR and time in therapeutic range (defined as >60%), the appropriate management is to either increase the intensity of the vitamin K antagonist (e.g., increase the INR target and range by 0.5 units) or add low-dose acetylsalicylic acid (75-100 mg/day). Direct oral anticoagulants and dual antiplatelet therapy alone are contraindicated for preventing thromboembolism in these patients.

Question 131

A 52-year-old female with a mechanical mitral valve prosthesis has been on lifelong vitamin K antagonist (VKA) therapy. She struggles with frequent clinic visits for International Normalized Ratio (INR) monitoring due to her demanding work schedule. She is highly motivated and asks her cardiologist about the possibility of INR self-monitoring at home. After ensuring she receives adequate training, the cardiologist discusses the expected outcomes of this approach. Which of the following best describes the clinical impact of INR self-monitoring compared to standard clinic-based monitoring?

• ○ It improves both the efficacy and safety of anticoagulation therapy.
• ✓ It increases the efficacy of anticoagulation therapy, but does not improve safety.
• ○ It increases the safety of anticoagulation therapy by reducing major bleeding, but does not improve efficacy.
• ○ It provides similar efficacy and safety but significantly reduces the overall cost of care.

Explanation. International normalized ratio (INR) self-monitoring and/or self-management in motivated and adequately trained patients has been shown to increase the efficacy of anticoagulation therapy, but it does not improve safety when compared with a standard clinic-based monitoring approach.

Question 132

A 68-year-old man with a mechanical mitral valve replacement is evaluated in the cardiology clinic. He is currently maintained on lifelong warfarin, a Vitamin K Antagonist (VKA), with consistently therapeutic International Normalized Ratio (INR) levels. He recently developed symptomatic peripheral artery disease with severe claudication. His overall bleeding risk is comprehensively evaluated and deemed to be low. Which of the following is the most appropriate antithrombotic management for this patient?

• ✓ Add low-dose acetylsalicylic acid (ASA) to the VKA therapy
• ○ Add clopidogrel to the VKA therapy
• ○ Maintain VKA monotherapy and increase the target INR
• ○ Transition from VKA to dual antiplatelet therapy with ASA and clopidogrel

Explanation. In patients with a mechanical heart valve who have an indication for single antiplatelet therapy due to symptomatic major atherosclerotic diseases and a low bleeding risk, the addition of low-dose acetylsalicylic acid (ASA) in combination with a Vitamin K Antagonist (VKA) is the appropriate strategy to significantly lower the incidence of major adverse cardiovascular events.

Question 133

A 62-year-old man with a mechanical aortic valve replacement requires an elective partial nephrectomy for a localized renal mass. He is currently on a vitamin K antagonist (VKA) for antithrombotic therapy. He has a normal left ventricular ejection fraction and no history of hypercoagulable states or prior thrombotic events. What is the most appropriate perioperative management strategy for his VKA therapy?

• ✓ Interrupt the VKA at least 4 days before surgery and resume within 24 hours or as soon as considered safe.
• ○ Interrupt the VKA 1 to 2 days before surgery and resume 48 to 72 hours postoperatively.
• ○ Continue the VKA uninterrupted at the current dose throughout the perioperative period.
• ○ Interrupt the VKA 7 days before surgery and withhold resumption until all surgical drains are removed.

Explanation. For patients with a mechanical heart valve undergoing surgery, the optimal perioperative management of antithrombotic therapy requires the interruption of the vitamin K antagonist (VKA) at least 4 days before the procedure, followed by resumption within 24 hours or as soon as it is considered clinically safe.

Question 134

A 64-year-old man with a mechanical mitral heart valve on a lifelong vitamin K antagonist (VKA) presents to the clinic for a routine laboratory follow-up. He reports feeling well and denies any recent trauma, melena, hematuria, or easy bruising. His vital signs are within normal limits, and physical examination reveals no signs of active bleeding. His laboratory results show an International Normalized Ratio (INR) of 11.2. Which of the following is the most appropriate management regarding his anticoagulation status?

• ✓ Temporarily cease the vitamin K antagonist and administer 2.0 to 3.0 mg of oral vitamin K1.
• ○ Temporarily cease the vitamin K antagonist and monitor closely without administering vitamin K1.
• ○ Administer 5.0 to 10.0 mg of oral vitamin K1 while continuing the current dose of the vitamin K antagonist.
• ○ Administer intravenous vitamin K1 and prothrombin complex concentrate.

Explanation. In non-bleeding patients taking a vitamin K antagonist who present with an International Normalized Ratio (INR) greater than 10.0, the administration of 2.0 to 3.0 mg of oral vitamin K1 is indicated to lower the INR safely while avoiding overcorrection.

Question 135

A 59-year-old male with a highly thrombogenic mechanical mitral heart valve (MHV) presents to the emergency department with uncontrolled, life-threatening gastrointestinal bleeding. He is currently taking a vitamin K antagonist (VKA). His blood pressure is 80/50 mmHg, heart rate is 120 beats per minute, and his international normalized ratio (INR) is 3.8. In addition to interrupting his VKA therapy, what is the most appropriate pharmacological strategy for rapidly reversing his anticoagulation?

• ○ Administer fresh frozen plasma and oral vitamin K1.
• ✓ Administer non-activated four-factor prothrombin complex concentrate at a starting dose of 12.5 IU/kg and intravenous vitamin K1.
• ○ Administer non-activated four-factor prothrombin complex concentrate at a starting dose of 25 IU/kg and oral vitamin K1.
• ○ Administer fresh frozen plasma and intravenous vitamin K1.

Explanation. Non-activated four-factor prothrombin complex concentrates provide safe and effective reversal of vitamin K antagonists in the setting of life-threatening bleeding. A reduced starting dose of 12.5 IU/kg is specifically selected for patients with highly thrombogenic mechanical heart valves. Intravenous vitamin K1 is co-administered because the intravenous route corrects the international normalized ratio approximately 4 hours faster than oral administration, which is critical in an acute bleeding emergency.

Question 136

A 62-year-old woman with a mechanical mitral heart valve (MHV) and atrial fibrillation (AF) is scheduled for an elective major non-cardiac surgery with a high bleeding risk. Her body mass index (BMI) is 42 kg/m². She is currently taking a vitamin K antagonist (VKA) for anticoagulation, and her baseline international normalized ratio (INR) is 3.0. She is considered to have a high thromboembolic risk. Which of the following is the most appropriate perioperative management strategy for her antithrombotic therapy?

• ✓ Interrupt VKA at least 4 days before surgery, start bridging with low-molecular-weight heparin (LMWH) when the INR becomes subtherapeutic, and manage LMWH dosing by measuring anti-Xa activity at peak and trough.
• ○ Interrupt VKA at least 7 days before surgery, start bridging with LMWH when the INR becomes subtherapeutic, and use a standard weight-based LMWH dose without laboratory monitoring.
• ○ Interrupt VKA 2 days before surgery, start bridging with unfractionated heparin (UFH), and administer four-factor prothrombin complex concentrate on the morning of surgery to ensure an INR <1.5.
• ○ Continue VKA until the day before surgery, and administer four-factor prothrombin complex concentrate to promptly correct the INR for the intervention.

Explanation. In patients with a mechanical heart valve and high thromboembolic risk undergoing non-cardiac, elective major invasive procedures with a high risk of bleeding, vitamin K antagonist (VKA) treatment must be interrupted at least 4 days before the procedure. Bridging with low-molecular-weight heparin (LMWH) should be initiated as soon as the international normalized ratio (INR) reaches a subtherapeutic value, aiming for an INR of <1.5 on the day of surgery. Furthermore, in selected patients, such as those with severe obesity or who are underweight, measuring anti-Xa activity at peak and trough is appropriate to properly manage LMWH dosing.

Question 137

A 62-year-old female presents to the cardiology clinic for preoperative clearance prior to a major abdominal surgery. She currently takes a vitamin K antagonist for anticoagulation, which will need to be interrupted due to the high bleeding risk of the planned surgery. The clinical team is evaluating whether she requires bridging anticoagulation. Which of the following underlying conditions specifically places this patient in a high thromboembolic risk category warranting bridging therapy?

• ○ A newer-generation mechanical heart valve in the aortic position
• ○ A cardioembolic stroke that occurred 18 months ago
• ○ Left ventricular ejection fraction of 42%
• ✓ Atrial fibrillation with significant mitral stenosis

Explanation. Atrial fibrillation accompanied by significant mitral stenosis is an established high-risk feature for thromboembolism that necessitates bridging anticoagulation during the temporary perioperative interruption of oral anticoagulants.

Question 138

A 45-year-old man with a new-generation mechanical aortic valve and no other risk factors for thromboembolism is scheduled for an elective partial colectomy. His current medication includes warfarin with a stable International Normalized Ratio (INR) of 2.5. What is the most appropriate approach to managing his anticoagulation perioperatively?

• ✓ Interrupt warfarin 3 to 4 days before surgery and resume within 24 hours post-operatively without bridging therapy.
• ○ Interrupt warfarin 5 days before surgery and bridge with therapeutic low-molecular-weight heparin until 24 hours before surgery.
• ○ Continue warfarin uninterrupted and perform the surgery while maintaining the INR between 2.0 and 3.0.
• ○ Transition from warfarin to a direct oral anticoagulant (DOAC) 7 days before surgery, pausing the DOAC 48 hours before the procedure.

Explanation. In patients with a mechanical heart valve and low cardioembolic risk (such as a new-generation mechanical valve in the aortic position without additional risk factors) undergoing elective major non-cardiac surgery, interrupting the vitamin K antagonist 3 to 4 days prior to surgery and resuming it within 24 hours post-operatively without the use of bridging therapy minimizes post-surgical bleeding without increasing the risk of thrombosis.

Question 139

A 78-year-old man undergoes uncomplicated transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis. His medical history includes hypertension, hyperlipidemia, and osteoarthritis. He has no history of atrial fibrillation, prior stroke, or venous thromboembolism, and his postoperative electrocardiogram confirms normal sinus rhythm. Which of the following is the most appropriate antithrombotic regimen for this patient?

• ✓ Lifelong low-dose acetylsalicylic acid (ASA) monotherapy
• ○ Dual antiplatelet therapy (DAPT) with ASA and clopidogrel for 6 months, followed by lifelong ASA
• ○ Low-dose rivaroxaban and ASA for 12 months, followed by lifelong ASA
• ○ Lifelong oral anticoagulation with apixaban monotherapy

Explanation. Lifelong low-dose ASA monotherapy is the recommended antithrombotic treatment after transcatheter aortic valve implantation (TAVI) in patients who do not have a baseline indication for oral anticoagulation. Single antiplatelet therapy with ASA has been shown to reduce the incidence of bleeding and the composite of bleeding or thromboembolic events compared with dual antiplatelet therapy (DAPT) at 1 year post-procedure.

Question 140

A 78-year-old male with severe, symptomatic tricuspid regurgitation, hypertension, and dyslipidemia undergoes successful transcatheter tricuspid valve implantation. Post-procedure, he remains in normal sinus rhythm and has no other baseline indications for systemic oral anticoagulation (OAC). What is the most appropriate antithrombotic regimen for this patient following the intervention?

• ✓ Initiation of oral anticoagulation (direct oral anticoagulant or vitamin K antagonist) for at least 6 months or indefinitely.
• ○ Single long-term antiplatelet therapy with aspirin.
• ○ Dual antiplatelet therapy with aspirin and clopidogrel for 3 months.
• ○ Low-dose rivaroxaban (10 mg/day) in combination with low-dose aspirin for 3 months.

Explanation. For patients without a baseline indication for oral anticoagulation who undergo tricuspid transcatheter valve implantation, oral anticoagulation (using either a direct oral anticoagulant or a vitamin K antagonist) is initiated and typically continued for at least 6 months or indefinitely.

Question 141

A 74-year-old man with a history of paroxysmal atrial fibrillation (AF) and severe symptomatic aortic stenosis undergoes a surgical aortic valve replacement using a bioprosthetic heart valve (BHV). Prior to surgery, he was maintained on apixaban, a direct oral anticoagulant (DOAC). His post-operative course is uncomplicated, and on post-operative day 2, the surgical team determines that he is hemodynamically stable with no signs of bleeding and it is surgically safe to resume oral medications. Which of the following is the most appropriate anticoagulation strategy for this patient?

• ✓ Restart apixaban immediately and continue as lifelong therapy.
• ○ Initiate a vitamin K antagonist with a target INR of 2.0-3.0 for the first 3 months, then switch back to apixaban.
• ○ Withhold all oral anticoagulants for 14 days to minimize bleeding risk, then resume apixaban.
• ○ Discontinue apixaban and initiate lifelong daily low-dose aspirin therapy.

Explanation. Lifelong oral anticoagulation is recommended for patients with surgical bioprosthetic heart valves who have other indications for oral anticoagulation, such as atrial fibrillation. Evidence supports the use of direct oral anticoagulants (DOACs) in preference to vitamin K antagonists in these patients, even during the early post-operative period. Pre-existing DOAC therapy should be restarted as soon as it is considered surgically safe, which is usually within 2 to 3 days of surgery.

Question 142

An 81-year-old woman with a history of permanent atrial fibrillation and severe symptomatic aortic stenosis undergoes an uncomplicated Transcatheter Aortic Valve Implantation (TAVI). Prior to the procedure, she was managed with a Vitamin K Antagonist (VKA) for stroke prevention. In determining her optimal antithrombotic regimen following the procedure, the medical team evaluates the risks of ischemic and bleeding events. Which of the following is the most accurate statement regarding her post-TAVI antithrombotic management?

• ✓ Continuing oral anticoagulation (OAC) alone is associated with a lower incidence of bleeding over 1 year compared to a regimen of OAC plus clopidogrel.
• ○ Transitioning from a VKA to edoxaban will lower her risk of major bleeding while providing non-inferior protection against ischemic events.
• ○ Transitioning from a VKA to apixaban is superior for reducing overall ischemic events and decreases the risk of non-cardiovascular mortality.
• ○ There is definitive evidence to recommend Direct Oral Anticoagulants (DOACs) over VKAs in all patients who have undergone TAVI with a pre-existing indication for OAC.

Explanation. In patients with a pre-existing indication for oral anticoagulation (OAC) who undergo Transcatheter Aortic Valve Implantation (TAVI), the use of OAC alone results in a lower incidence of bleeding over a period of 1 month or 1 year compared to the combination of OAC plus clopidogrel, while maintaining non-inferiority with respect to ischemic events.

Question 143

An 81-year-old male with a history of persistent atrial fibrillation (AF) and severe, symptomatic tricuspid regurgitation undergoes a successful transcatheter tricuspid valve implantation. Prior to the procedure, he was stably maintained on a direct oral anticoagulant (DOAC) for stroke prevention. His procedural course is uncomplicated. What is the most appropriate approach to his antithrombotic therapy following the intervention?

• ○ Discontinue the DOAC and initiate dual antiplatelet therapy (DAPT) for 6 months.
• ✓ Continue the pre-existing DOAC regimen, while taking into consideration his bleeding risk.
• ○ Switch from the DOAC to a vitamin K antagonist (VKA) with a target INR of 2.5-3.5.
• ○ Continue the DOAC and routinely add acetylsalicylic acid (ASA) indefinitely.

Explanation. In patients undergoing transcatheter tricuspid valve implantation who are already receiving oral anticoagulation for atrial fibrillation, common practice is to continue the pre-existing anticoagulation regimen (such as a DOAC), taking into careful consideration the high bleeding risk that is characteristic of this usually elderly population.

Question 144

A 68-year-old woman presents to the cardiology clinic for a routine follow-up 4 years after undergoing transcatheter aortic valve implantation with a bioprosthetic heart valve. She is currently asymptomatic and reports good exercise tolerance. You are reviewing her serial transthoracic echocardiography (TTE) reports to assess for early signs of structural valve deterioration, which can present as leaflet fibrosis, calcification, or stent deformation. To accurately detect early structural valve deterioration, the current TTE findings should ideally be compared to a baseline study obtained at which of the following time points?

• ○ Intraoperative transesophageal echocardiogram immediately following valve deployment
• ✓ At the time of hospital discharge, or within 1 to 3 months after valve implantation
• ○ Six months after valve implantation, once left ventricular reverse remodeling is complete
• ○ One year after valve implantation, to account for complete endothelialization of the prosthesis

Explanation. To ensure timely diagnosis of structural valve deterioration, serial echocardiographic measurements should be performed and compared with a baseline transthoracic echocardiogram obtained at the time of hospital discharge, or within 1 to 3 months after valve implantation.

Question 145

An 81-year-old female with a history of surgical aortic valve replacement using a 19 mm bioprosthesis 12 years ago presents with new-onset exertional dyspnea and fatigue. Advanced imaging with transoesophageal echocardiography (TOE) and cardiac computed tomography (CCT) confirms structural valve deterioration (SVD) of the bioprosthesis with severe stenosis. The interdisciplinary Heart Team is considering a transcatheter valve-in-valve (ViV) implantation. Given the size of her degenerated bioprosthesis, which of the following represents a major anatomical consideration that must be anticipated and may impact the intervention strategy?

• ✓ The creation of prosthesis-patient mismatch (PPM)
• ○ The high risk of device embolization
• ○ The development of severe paravalvular leak (PVL)
• ○ The inability to adequately pace the patient post-procedure

Explanation. When evaluating a patient for a transcatheter valve-in-valve procedure to treat a degenerated aortic bioprosthetic valve, the possibility of creating a prosthesis-patient mismatch (PPM) in originally small valves must be anticipated, as this can significantly impact the planned intervention or valve selection.

Question 146

A 76-year-old woman with a history of bioprosthetic mitral valve replacement 12 years ago presents with worsening dyspnea and fatigue. Echocardiography reveals severe structural valve deterioration of the bioprosthesis with severe mitral regurgitation. Her left ventricle is small and significantly hypertrophied with a preserved ejection fraction. The Heart Team is considering a transfemoral transseptal mitral valve-in-valve implantation. Which of the following potential complications must be most carefully evaluated and ruled out prior to proceeding with the intervention?

• ✓ Left ventricular outflow tract (LVOT) obstruction
• ○ Severe paravalvular leak (PVL)
• ○ Prosthesis-patient mismatch (PPM)
• ○ Leaflet entrapment by chordae

Explanation. In the setting of transcatheter mitral valve-in-valve implantation, there is a risk of left ventricular outflow tract (LVOT) obstruction. Although infrequent, this potential complication must be carefully evaluated and ruled out beforehand, particularly in patients who have small and hypertrophic left ventricles.

Question 147

A 62-year-old man presents with worsening exertional dyspnea one year after undergoing surgical aortic valve replacement. Echocardiography reveals a normal left ventricular ejection fraction and a well-seated bioprosthetic valve with no evidence of structural valve deterioration, thrombus, or paravalvular leak. However, the indexed effective orifice area (EOA) is 0.58 cm²/m², consistent with severe prosthesis-patient mismatch (PPM). His surgical risk is evaluated and deemed to be low. What is the most appropriate management approach for this patient?

• ✓ Consider reoperation for valve replacement.
• ○ Reassure the patient and continue current medical therapy.
• ○ Initiate systemic anticoagulation with a vitamin K antagonist.
• ○ Delay intervention until objective signs of structural valve deterioration occur.

Explanation. Reoperation is indicated and should be considered in symptomatic patients who have severe prosthesis-patient mismatch, particularly when the patient is at low surgical risk.

Question 148

A 65-year-old female with a history of a mechanical mitral valve replacement presents with progressive fatigue. Laboratory analysis reveals a hemoglobin of 7.8 g/dL, significantly elevated lactate dehydrogenase, and undetectable haptoglobin. She has required two blood transfusions in the past month. A transthoracic echocardiogram (TTE) demonstrates normal mechanical leaflet motion but is inconclusive regarding the presence of a paravalvular leak (PVL). What is the most appropriate next step in evaluation and the corresponding indication for intervention in this patient?

• ✓ Perform a transoesophageal echocardiogram (TOE) to diagnose PVL; intervention is indicated because the haemolysis requires blood transfusions.
• ○ Proceed with fluoroscopy to assess mechanical leaflet motion; intervention is only indicated if there is evidence of structural valve deterioration.
• ○ Initiate medical therapy with iron supplementation and erythropoietin; intervention is reserved exclusively for PVL secondary to endocarditis.
• ○ Repeat the transthoracic echocardiogram (TTE) with contrast; intervention is indicated only if the patient develops refractory heart failure.

Explanation. Transoesophageal echocardiography is required for the definitive diagnosis of a paravalvular leak, as transthoracic echocardiography is often inconclusive. In patients with paravalvular leaks, intervention is specifically indicated when haemolysis is severe enough to require blood transfusions.

Question 149

A 72-year-old woman with a history of severe symptomatic aortic stenosis underwent transcatheter aortic valve implantation (TAVI) 18 months ago. She is currently asymptomatic and takes a daily low-dose aspirin. She is scheduled to undergo a dental extraction for a non-restorable tooth. She has no prior history of infective endocarditis. Which of the following is the most appropriate recommendation regarding infective endocarditis prophylaxis prior to her dental procedure?

• ✓ Antibiotic prophylaxis is recommended prior to the procedure.
• ○ Antibiotic prophylaxis is not recommended, as it is only indicated for patients with mechanical heart valves.
• ○ Antibiotic prophylaxis is not recommended, as transcatheter valves do not require prophylaxis in the absence of prior infective endocarditis.
• ○ Antibiotic prophylaxis is only recommended if purulent discharge or active infection is present at the extraction site.

Explanation. Antibiotic prophylaxis is recommended in all patients with a prosthetic valve, which explicitly includes transcatheter valve prostheses. This prophylaxis is indicated when these patients undergo dental extractions, oral surgery, or other procedures requiring manipulation of the gingival or peri-apical region of the teeth, regardless of whether they have a prior history of infective endocarditis.

Question 150

A 74-year-old man presents with progressive exertional dyspnea one year after undergoing surgical aortic valve replacement with a bioprosthetic heart valve. A transthoracic echocardiogram reveals an unexpected, relevant increase in transvalvular gradients compared to his baseline postoperative study. Subsequent cardiac computed tomography confirms the presence of hypo-attenuated leaflet thickening (HALT) and restricted leaflet motion. What is the most appropriate next step in management to resolve these findings?

• ✓ Initiate therapy with a direct oral anticoagulant (DOAC) or a vitamin K antagonist (VKA)
• ○ Refer the patient for urgent surgical valve replacement
• ○ Start dual antiplatelet therapy with aspirin and clopidogrel
• ○ Administer intravenous thrombolytic therapy with alteplase

Explanation. In patients with bioprosthetic heart valves who develop relevant increases in transvalvular gradients, and in whom hypo-attenuated leaflet thickening (HALT) with restricted leaflet motion is confirmed by cardiac computed tomography, the elective use of direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs) is indicated to resolve the leaflet thrombosis.

Question 151

A 45-year-old woman with a mechanical mitral valve presents to the emergency department with an acute episode of expressive aphasia that completely resolves within 2 hours. A transesophageal echocardiogram demonstrates normal motion of the mechanical valve leaflets, but identifies a 14 mm non-obstructive thrombus attached to the prosthetic sewing ring. She does not have any symptoms of heart failure. Which of the following is the most appropriate management?

• ✓ Surgical intervention
• ○ Administration of systemic fibrinolysis via slow, low-dose infusion
• ○ Optimization of oral anticoagulation and addition of clopidogrel
• ○ Observation with strict adherence to a higher target international normalized ratio (INR)

Explanation. Surgical intervention is the indicated treatment for a large (greater than 10 mm) non-obstructive prosthetic valve thrombus that is complicated by an embolic event.

Question 152

A 78-year-old man with known severe asymptomatic aortic stenosis (a significant valvular heart disease) is evaluated prior to undergoing an urgent non-cardiac surgery for a bowel obstruction. His left ventricular ejection fraction is 50%. The surgical team requests a cardiology consultation to assess his risk of peri-operative cardiovascular complications. Based on the fundamental principles of evaluating such patients, which of the following combinations of factors primarily dictates his increased cardiovascular risk during this period?

• ✓ The timing of the procedure, the type of surgery, and patient-specific factors including the type and severity of the valvular lesion and left ventricular function.
• ○ The duration of the general anesthesia, the patient's baseline hemoglobin, and the specific choice of anesthetic agents.
• ○ The anticipated intra-operative blood loss, the patient's age, and the presence of underlying conduction abnormalities.
• ○ The availability of intra-operative transoesophageal echocardiography, the use of invasive hemodynamic monitoring, and the patient's functional capacity.

Explanation. In patients with significant valvular heart disease undergoing non-cardiac surgery, the risk of peri-operative cardiovascular complications is increased and is directly related to the timing of the procedure (e.g., urgent versus non-urgent), the type of surgery (low, intermediate, or high risk), and patient-specific factors such as the type and severity of the valvular heart disease and left ventricular function.

Question 153

A 78-year-old male with a known history of severe, symptomatic aortic stenosis presents to the emergency department with a ruptured abdominal aortic aneurysm. The surgical team determines that immediate, life-saving, time-sensitive non-cardiac surgery is required. He has a history of exertional dyspnea and angina. His blood pressure is 90/50 mmHg and heart rate is 105 bpm. Which of the following is the most appropriate management strategy regarding his aortic stenosis in this scenario?

• ✓ Proceed with the life-saving non-cardiac surgery under careful haemodynamic monitoring, avoiding rapid changes of volume status, and promptly treating arrhythmias.
• ○ Delay the non-cardiac surgery to perform an urgent balloon aortic valvuloplasty to temporarily reduce the transvalvular gradient.
• ○ Perform an emergent transcatheter aortic valve implantation (TAVI) prior to proceeding with the non-cardiac surgery.
• ○ Initiate medical management with positive inotropes and delay the non-cardiac surgery until a multidisciplinary heart team discussion can occur.

Explanation. In patients with severe symptomatic aortic stenosis who require life-saving, time-sensitive non-cardiac surgery, the recommended approach is to proceed with the surgery without delay under careful haemodynamic monitoring. Management must focus on avoiding rapid changes in volume status and ensuring prompt treatment of any arrhythmias, regardless of the severity of the aortic stenosis.

Question 154

A 65-year-old female presents for preoperative evaluation prior to an elective open pancreaticoduodenectomy, a high-risk non-cardiac surgery (NCS). She reports a recent onset of exertional dyspnea over the past two months. Transthoracic echocardiography reveals rheumatic mitral valve changes with a mitral valve area (MVA) of 1.3 cm^2 and a systolic pulmonary artery pressure (SPAP) of 42 mmHg. What is the most appropriate management regarding her valvular heart disease prior to the planned surgery?

• ✓ Perform percutaneous mitral commissurotomy (PMC) or another appropriate valve intervention prior to the surgery.
• ○ Proceed with the surgery with careful intraoperative monitoring, as her SPAP is less than 50 mmHg.
• ○ Proceed with the surgery while initiating arterial vasodilators to optimize forward flow and reduce pulmonary pressures.
• ○ Defer the non-cardiac surgery and manage medically, as high-risk surgery is contraindicated with an MVA less than 1.5 cm^2.

Explanation. Symptomatic patients with significant mitral stenosis (mitral valve area less than or equal to 1.5 cm^2) should undergo percutaneous mitral commissurotomy or another appropriate valve intervention before high-risk non-cardiac surgery to reduce perioperative risk.

Question 155

A 72-year-old male with a history of heart failure with reduced ejection fraction and severe ventricular secondary mitral regurgitation (SMR) is evaluated in the preoperative clinic. He is scheduled for an elective open hemicolectomy for a benign polyp, which is considered an intermediate-risk non-cardiac surgery. His guideline-directed medical therapy for heart failure has been fully optimized, yet he continues to experience significant exertional dyspnea (New York Heart Association class III). What is the most appropriate next step in management prior to the planned surgery?

• ○ Proceed directly with the elective surgery under strict haemodynamic monitoring without prior valve intervention.
• ✓ Consider transcatheter edge-to-edge repair (TEER) after a Heart Team discussion.
• ○ Perform routine pulmonary artery catheterization to optimize fluid management during the surgery.
• ○ Proceed with surgical mitral valve replacement prior to the non-cardiac surgery.

Explanation. In cases of elective, intermediate- or high-risk non-cardiac surgery in patients with severe ventricular secondary mitral regurgitation whose symptoms persist despite optimized medical therapy, transcatheter edge-to-edge repair (TEER) should be considered after a Heart Team discussion based on clinical and anatomical selection criteria.

Question 156

A 26-year-old female presents for pre-pregnancy counseling. During her physical examination, a low-pitched diastolic murmur is auscultated at the cardiac apex. A 12-lead Electrocardiogram (ECG) shows right axis deviation and broad P waves. Suspecting Valvular Heart Disease (VHD), her physician refers her to a cardiologist. A Transthoracic Echocardiogram (TTE) confirms moderate rheumatic mitral stenosis. She is eager to start a family soon and asks about the potential dangers of pregnancy given her newly diagnosed heart condition. What is the most appropriate approach to formalize her maternal risk?

• ✓ Utilize the modified World Health Organization (WHO) classification, CARPREG, or DEVI risk scores to quantify the maternal risk.
• ○ Assess the surgical risk of urgent mitral valve intervention using the EuroSCORE II and STS risk models before conception.
• ○ Advise permanent contraception as pregnancy is universally contraindicated in patients with diagnosed Valvular Heart Disease (VHD).
• ○ Recommend immediate conception without further risk stratification since asymptomatic moderate Valvular Heart Disease (VHD) poses no significant maternal risk.

Explanation. In patients with Valvular Heart Disease (VHD) who are contemplating pregnancy, pre-pregnancy counseling is imperative and formal maternal risk assessment should be conducted using specific, established clinical tools such as the modified World Health Organization (WHO) classification, the CARPREG score, or the DEVI risk score.

Question 157

A 28-year-old woman with a history of childhood rheumatic fever presents for pre-conception counseling. She is completely asymptomatic, exercises vigorously five days a week without dyspnea, and takes no daily medications. A comprehensive transthoracic echocardiogram reveals rheumatic mitral stenosis with a calculated mitral valve area of 1.3 cm², a mean transmitral gradient of 8 mmHg, and a normal left ventricular ejection fraction. Which of the following is the most appropriate recommendation regarding her pregnancy plans?

• ○ Proceed with pregnancy and schedule serial transthoracic echocardiograms every trimester.
• ○ Perform exercise stress testing to objectively confirm her asymptomatic status before conception.
• ✓ Prophylactic correction of the mitral stenosis prior to conception.
• ○ Proceed with pregnancy and initiate prophylactic beta-blocker therapy.

Explanation. Before recommending pregnancy, mitral stenosis with a mitral valve area of less than 1.5 cm² requires structural correction prior to conception, even in patients who are completely asymptomatic.

Question 158

A 27-year-old woman presents for preconception counseling. She has a history of rheumatic heart disease and is diagnosed with severe mitral stenosis. She is currently asymptomatic at rest but experiences mild dyspnea with moderate exertion. Echocardiography demonstrates a mitral valve area of 1.2 cm², a favorable valve morphology for percutaneous intervention, and no left atrial thrombus. She strongly desires to become pregnant in the near future. Which of the following is the most appropriate primary intervention for her valvular disease?

• ✓ Percutaneous mitral commissurotomy
• ○ Surgical mitral valve replacement with a mechanical prosthesis
• ○ Surgical mitral valve replacement with a bioprosthetic prosthesis
• ○ Close observation with serial echocardiograms during pregnancy

Explanation. The first therapeutic option for mitral stenosis in a woman considering pregnancy is percutaneous mitral commissurotomy. Intervention is indicated prior to conception because pregnancy can worsen the clinical course of left-sided stenotic valvular lesions; the physiological increase in cardiac output during pregnancy causes an increment of the transvalvular gradient of approximately 50%, predominantly between the first and second trimesters.

Question 159

A 28-year-old pregnant woman at 26 weeks of gestation presents to the clinic with worsening dyspnea on minimal exertion. Echocardiography reveals severe rheumatic mitral stenosis with a mitral valve area of 0.9 cm² and a systolic pulmonary artery pressure (SPAP) of 56 mmHg. She remains highly symptomatic despite being perfectly compliant with an optimal medical regimen consisting of diuretics and a beta-1-selective beta-blocker. Which of the following is the most appropriate next step in her management?

• ✓ Percutaneous mitral commissurotomy
• ○ Surgical mitral valve replacement under cardiopulmonary bypass
• ○ Scheduled early Cesarean section at 28 weeks
• ○ Transitioning from a beta-1-selective beta-blocker to a non-selective beta-blocker

Explanation. In pregnant patients with mitral stenosis who continue to experience symptoms or have a systolic pulmonary artery pressure (SPAP) greater than 50 mmHg despite receiving optimal medical therapy with diuretics and beta-1-selective beta-blockers, percutaneous mitral commissurotomy is the indicated procedure to alleviate the obstruction, ideally performed after the 20th week of gestation.

Question 160

A 28-year-old woman with a mechanical aortic valve presents for her first prenatal visit at 6 weeks gestation. Prior to pregnancy, she was maintained on a warfarin dose of 7.5 mg daily to achieve her target international normalized ratio (INR). She is asymptomatic, and her echocardiogram shows normal mechanical valve function. What is the most appropriate anticoagulation strategy for this patient during the first trimester?

• ○ Continue warfarin at 7.5 mg daily with frequent INR monitoring.
• ✓ Switch to dose-adjusted low molecular weight heparin (LMWH) at least twice daily with strict anti-Xa monitoring.
• ○ Switch to a prophylactic dose of low molecular weight heparin (LMWH) once daily.
• ○ Transition to continuous intravenous unfractionated heparin (UFH) for the duration of the first trimester.

Explanation. In pregnant patients with a mechanical heart valve who require a warfarin dose of greater than 5 mg/day, the recommended strategy is to switch to dose-adjusted low molecular weight heparin (LMWH) at least twice per day with strict anti-Xa monitoring during the first trimester. This approach is necessary to avoid the teratogenic effects associated with higher doses of vitamin K antagonists while ensuring therapeutic anticoagulation to prevent valve thrombosis.

Question 161

A 76-year-old female presents with progressive shortness of breath. Echocardiography demonstrates an aortic valve area of 0.8 cm², a mean transvalvular gradient of 32 mmHg, and a left ventricular ejection fraction (LVEF) of 68%. The left ventricle exhibits severe concentric hypertrophy and a small cavity size. Her stroke volume index is calculated at 33 mL/m². Given the discordant echocardiographic parameters and the suspicion for severe paradoxical low-flow, low-gradient aortic stenosis, what is the most appropriate next diagnostic step?

• ✓ Perform cardiac computed tomography (CCT) to quantify the aortic valve calcium score.
• ○ Perform a dobutamine stress echocardiogram to determine if there is a true flow limitation.
• ○ Proceed directly to invasive coronary angiography to evaluate for an ischemic etiology.
• ○ Recommend conservative management with a repeat echocardiogram in 6 to 12 months.

Explanation. Cardiac computed tomography (CCT) is indicated to quantify the calcium score in women with discordant echocardiographic parameters, as female patients frequently develop concentric ventricular hypertrophy and a smaller left ventricular cavity, which predisposes them to paradoxical low-flow, low-gradient constellations that can complicate the diagnosis of severe aortic stenosis.